

# Q1 2024 REPORT



A VITAL LINK  
IN HEALTHCARE



**ANDLAUER HEALTHCARE GROUP INC.**

**Management's Discussion and Analysis  
of Financial Condition and Results of Operations  
for the three-month periods ended March 31, 2024 and 2023**

**May 2, 2024**

## **TABLE OF CONTENTS**

<b>Cautionary Note Regarding Forward-Looking Information .....</b>	<b>3</b>
<b>Basis of Presentation .....</b>	<b>5</b>
<b>Non-IFRS Measures .....</b>	<b>5</b>
<b>Overview.....</b>	<b>6</b>
<b>Summary of Factors Affecting Performance .....</b>	<b>7</b>
<b>How We Assess the Performance of Our Business .....</b>	<b>11</b>
<b>Selected Consolidated Financial Information.....</b>	<b>14</b>
<b>Reconciliation of Non-IFRS Measures.....</b>	<b>16</b>
<b>Results of Operations .....</b>	<b>16</b>
<b>Summary of Quarterly Results .....</b>	<b>20</b>
<b>Liquidity &amp; Capital Resources.....</b>	<b>21</b>
<b>Cash Flows .....</b>	<b>25</b>
<b>Contractual Obligations.....</b>	<b>26</b>
<b>Off-Balance Sheet Arrangements .....</b>	<b>26</b>
<b>Seasonality.....</b>	<b>26</b>
<b>Financial Instruments .....</b>	<b>27</b>
<b>Related Party Transactions.....</b>	<b>28</b>
<b>Critical Accounting Judgements and Estimates .....</b>	<b>30</b>
<b>Significant New Accounting Standards .....</b>	<b>31</b>
<b>Accounting Classifications and Fair Values .....</b>	<b>31</b>
<b>Risk Factors.....</b>	<b>32</b>
<b>Outstanding Share Data.....</b>	<b>33</b>
<b>Disclosure Controls and Procedures and Internal Controls Over Financial Reporting .....</b>	<b>34</b>
<b>Additional Information .....</b>	<b>35</b>

## MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management's discussion and analysis of financial condition and results of operations ("MD&A") for the three-month periods ended March 31, 2024 and 2023 should be read in conjunction with Andlauer Healthcare Group Inc.'s unaudited interim condensed consolidated financial statements for the three-month periods ended March 31, 2024 and 2023, along with the related notes thereto and the audited annual consolidated financial statements, related notes thereto and MD&A for the years ended December 31, 2023 and 2022. This MD&A is presented as of May 2, 2024 and is current to that date unless otherwise stated.

All references in this MD&A to the "Company", "AHG", "us", "our" or "we" refer to Andlauer Healthcare Group Inc., together with our direct and indirect subsidiaries, on a consolidated basis, which is referred to as "the Company" in our financial statements. Additionally, all references to "Q1 2024" are to the three months ended March 31, 2024; "Q1 2023" are to the three months ended March 31, 2023; "Q4 2023" are to the three months ended December 31, 2023; "Q4 2022" are to the three months ended December 31, 2022; "Q4 2021" are to the three months ended December 31, 2021; "Q3 2023" are to the three months ended September 30, 2023; "Q3 2022" are to the three months ended September 30, 2022; "Q2 2023" are to the three months ended June 30, 2023; "Q2 2022" are to the three months ended June 30, 2022; "Fiscal 2025" are to the year ending December 31, 2025; "Fiscal 2024" are to the year ending December 31, 2024; "Fiscal 2023" are to the year ended December 31, 2023; "Fiscal 2022" are to the year ended December 31, 2022, and "Fiscal 2021" are to the year ended December 31, 2021.

### Cautionary Note Regarding Forward-Looking Information

This MD&A contains forward-looking information and forward-looking statements (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information may relate to our future financial outlook and anticipated events or results and may include information regarding our financial position, business strategy, growth strategies, addressable markets, budgets, operations, financial results, taxes, dividend policy, plans, objectives, and expectations with respect to the coronavirus disease ("COVID-19"), our Credit Facilities, our WMS and our ESG reporting (each as defined below). Particularly, information regarding our expectations of future results, performance, achievements, facility expansions, leases, platform expansions, acquisitions, public company costs, payment of dividends, prospects, financial targets or outlook, intentions, opportunities, activity under the NCIB and ASPP (each as defined below) and the markets in which we operate is forward-looking information. In some cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "budget", "scheduled", "estimates", "outlook", "forecasts", "projection", "prospects", "strategy", "intends", "anticipates", "does not anticipate", "believes", "commencing" or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "will", "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events or circumstances.

Such forward-looking statements are qualified in their entirety by the inherent risks, uncertainties and changes in circumstances surrounding future expectations which are difficult to predict and many of which are beyond the control of the Company.

This forward-looking information and other forward-looking information is based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct.

Forward-looking information is necessarily based on a number of opinions, estimates and assumptions that, while considered by the Company to be appropriate and reasonable as of the date of this MD&A, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to:

- the impact of inflation and rising interest rates together with the threats of stagflation or recession;
- the uncertainties in the global economy created by the war in Ukraine and in the Middle East, including the Israel-Hamas war;
- the impact of variation in the value of the Canadian dollar in relation to the U.S. dollar;
- the impact of changing conditions in the healthcare logistics and transportation services market;
- risks and liabilities associated with the transportation of dangerous goods;
- our ability to comply with U.S. foreign ownership, control or influence mitigation measures;
- our ability to execute our growth strategies;
- increasing competition in the healthcare logistics and transportation services market in which we operate;
- volatility in financial markets;
- changes in the attitudes, financial condition and demand of our target markets;
- developments and changes in applicable laws and regulations;
- our ability to source and complete acquisitions;
- our ability to successfully integrate businesses and assets that we acquire and realize synergies;
- our ability to retain and grow revenue with existing clients and develop new clientele;
- our ability to retain members of our management team and key personnel;
- increases in driver compensation and the ability to attract and retain employees;
- the availability of equipment and drivers in the markets in which we operate;
- the possibility of a cyber attack impacting our information systems;
- our ability to expand into additional markets; and
- such other factors discussed in greater detail under “Risk Factors” in this MD&A and in our Annual Information Form dated March 5, 2024 for Fiscal 2023 (the “AIF”) which is available on our profile on the System for Electronic Document Analysis and Retrieval (“SEDAR+”) at [www.sedarplus.ca](http://www.sedarplus.ca).

If any of these risks or uncertainties materialize, or if the opinions, estimates, or assumptions underlying the forward-looking information prove incorrect, actual results or future events might vary materially from those anticipated in the forward-looking information. The opinions, estimates or assumptions referred to above and described in greater detail in “Risk Factors” should be considered carefully by prospective investors.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and allowing investors and others to get a better understanding of our anticipated financial position, results of operations and operating environment. Readers are cautioned that such information may not be appropriate for other purposes.

Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not presently known to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, investors should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this MD&A represents our expectations as of the date of this MD&A (or as of the date they are otherwise stated to be made) and are subject to change after such date. However, we disclaim any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws.

**All of the forward-looking information contained in this MD&A is expressly qualified by the foregoing cautionary statements.**

### **Basis of Presentation**

Our unaudited interim condensed consolidated financial statements as at and for the three-month periods ended March 31, 2024 and 2023 have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting, as issued by the International Accounting Standards Board (“IASB”). Under International Financial Reporting Standards (“IFRS”), additional disclosures are required in the annual financial statements and therefore, our unaudited interim condensed consolidated financial statements and accompanying notes should be read in conjunction with the notes to our audited annual consolidated financial statements for the years ended December 31, 2023 and 2022.

Our unaudited interim condensed consolidated financial statements have been prepared using consistent accounting policies and methods used in the preparation of our audited annual consolidated financial statements.

### **Non-IFRS Measures**

This MD&A refers to certain non-IFRS measures. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of our results of operations from management’s perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. We use non-IFRS measures including “EBITDA” and “EBITDA Margin”. These non-IFRS measures are used to provide investors with supplemental measures of our operating performance and thus highlight trends in our core business that may not otherwise be apparent when relying solely on IFRS financial measures. We also believe that securities analysts, investors, and other interested parties frequently use non-IFRS measures in the evaluation of issuers. Our management also uses non-IFRS measures to facilitate operating performance comparisons from period to period, to prepare annual operating budgets and to determine components of management compensation.

For a description of how we define these non-IFRS Measures and an explanation of why the non-IFRS measures provide useful information to investors, please see “How We Assess the Performance of Our Business – Non-IFRS Measures” below.

For quantitative reconciliations of net income to EBITDA for Q1 2024 and Q1 2023, please see “Reconciliation of Non-IFRS Measures” below.

## Overview

AHG was incorporated under the *Business Corporations Act* (Ontario) on November 12, 2019, with its head office located at 100 Vaughan Valley Blvd, Woodbridge, ON, L4H 3C5. The Company's subordinate voting shares ("Subordinate Voting Shares") are listed on the Toronto Stock Exchange (the "TSX") under the stock symbol "AND".

We are a leading and growing supply chain management company with a platform of customized third-party logistics ("3PL") and specialized transportation solutions for the healthcare sector. We offer services to healthcare manufacturers, wholesalers, distributors and 3PL providers, among others, through a comprehensive platform of high quality, technology-enabled supply chain solutions for a range of products, including: pharmaceuticals, vaccines, biologics, blood products, narcotics, precursors, active pharmaceutical ingredients, over-the-counter, natural health, animal health, consumer health, cosmetics, health and beauty aids, and medical devices. We integrate our uniquely designed Canada-wide network of facilities, vehicles, personnel, and technology systems into our clients' businesses to offer holistic solutions that span all of our clients' shipping needs and satisfy the requirements of the highly regulated Canadian healthcare sector. During Fiscal 2021, we expanded our specialized transportation capabilities, through acquisitions, into truckload services for the healthcare sector in the United States.

We differentiate our service offerings and deliver value to our clients through our competitive strengths in temperature management, quality assurance and regulatory compliance, technology-enabled visibility throughout the supply chain and security. We are committed to developing and expanding long-term strategic relationships with our clients to provide improved operational efficiencies and access to value-added services. We generate revenue across five principal product lines: logistics and distribution, packaging solutions, air freight forwarding, ground transportation, and dedicated and last mile delivery.

We believe that we are Canada's only national third-party service provider focused exclusively on delivering customized, end-to-end logistics and specialized transportation solutions to the healthcare sector. Our 3PL services are provided under our Accuristix and LSU brands, through which we provide customized logistics, distribution and packaging solutions to various healthcare manufacturers. Our specialized transportation solutions are offered under our ATS Healthcare, ATS Dedicated and Skelton brands in Canada, where we provide a one-stop shop for our clients' healthcare transportation needs through our specialized air freight forwarding, ground transportation, dedicated delivery and last mile services. We believe we are a national leader in the Canadian healthcare logistics and specialized transportation markets we serve.

We also provide specialized transportation services domestically in the United States under our Boyle Transportation and Skelton USA brands (each as defined below). Boyle Transportation provides specialized transportation services to clients in the life sciences (approximately 70-75% of revenue) and government/defense sectors (approximately 25-30% of revenue). Boyle Transportation adheres to stringent quality and security standards, employs highly trained and dedicated professionals, continually invests in advanced technology and equipment, and has an expansive reach across the United States. Skelton USA was launched in 2017 and has grown by successfully leveraging its Canadian reputation and brand for expertise in cold chain services. Skelton USA currently serves customers across the United States.

In our healthcare logistics segment, we serve as an extension of our manufacturing clients, leveraging our infrastructure and expertise to manage their supply chain activities, allowing them to focus on other strategic priorities such as sales, marketing, research and development. We focus on serving our logistics clients as comprehensively as possible and incorporate multiple services from all of our related product lines into our customized logistics solutions.

In our specialized transportation segment, we leverage our national infrastructure in Canada to offer coast-to-coast delivery, including specialized facilities, multiple modes of transportation and flexible capacity to accommodate the full range of our clients' logistics and/or transportation needs on an integrated and efficient basis. By combining multiple service offerings, we can effectively provide managed and monitored movement of our clients' temperature sensitive and valuable products through a closed-loop nation-wide system.

Our competitive strengths in temperature management, quality assurance and regulatory compliance, visibility throughout the supply chain and security are deployed across our Canada-wide network of 32 secure, temperature-controlled facilities, the seven third-party owned cross-docks that we operate from and by our team of highly trained employees. Our security, information and monitoring systems, as well as our temperature management expertise, allow us to meet and exceed Health Canada guidelines and regulations, ensuring the integrity and quality of our clients' temperature sensitive healthcare goods and data.

We also have four facilities in the United States.

Additional information about AHG, including our AIF, can be found on our profile on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca) or on our website at [www.andlauerhealthcare.com](http://www.andlauerhealthcare.com).

## **Summary of Factors Affecting Performance**

We believe that our performance and future success depend on a number of factors that present significant opportunities for us. These factors are also subject to a number of inherent risks and challenges, some of which are discussed below and in the "Risk Factors" section of this MD&A and in our AIF.

### *Service Offering*

We believe that offering a platform of services designed specifically for the healthcare sector puts us in a unique position as a provider of supply chain solutions. Our competitive strengths in temperature management, quality assurance and regulatory compliance, visibility throughout the supply chain and security allow us to provide healthcare clients with specialized, integrated, end-to-end supply chain solutions. Through our five principal, complementary service offerings: logistics and distribution, packaging solutions, air freight forwarding, ground transportation, and dedicated and last mile delivery, we accommodate our clients' specialized supply chain needs on an integrated and efficient basis.

### *Relationships with Manufacturers and Distributors*

We believe that our market position is strengthened by the desire of our clients to increasingly outsource their supply-chain management to specialized service providers with the healthcare quality systems, operational expertise, and experience to efficiently optimize their product distribution. We are committed to developing and expanding long-term strategic relationships with our clients to provide improved operational efficiencies and access to value-added services. From manufacturers to distributors to retail locations to front doors across Canada and the United States, we store, transport, and monitor and manage the temperature conditions of a range of healthcare products. Our trained personnel comply with healthcare industry regulations and best practices.

### *New Development Projects*

We secure client contract wins as a foundation for growth and then add incremental warehousing and distribution square footage through capital efficient leases. Given the required lead-time to build and license facilities, as we secure new major client contracts, we typically strategically invest in excess capacity in anticipation of growing client needs, as well as new client opportunities, which enables capital efficient growth.

### *Demographics and Healthcare Spending*

We believe that we are strategically positioned to directly benefit from the strong growth expected in the North American healthcare sector, which is driven by a number of favourable trends including an aging population, increased life expectancy, increasing healthcare spending, and an increasing number of healthcare products requiring unique logistics needs. Vaccines and biologics, for example, are generally temperature sensitive and require varying degrees of temperature conditions for transportation and storage.

### *Regulatory Environment*

In order to maintain the safety, quality and efficacy of healthcare products, government regulations set out rules relating to, among other things, the packaging, warehousing, distribution, transportation and temperature monitoring of such products. The pace of introduction and complexity of such regulations has increased in recent years, including through the introduction of, and revisions to, many Health Canada guidelines, such as Health Canada's GUI-0069 - Guidelines for Environmental Control of Drugs During Storage and Transportation ("GUI-0069"), among others. Recognizing the ever-changing regulatory demands on the healthcare sector, we take a proactive approach to stay aligned with regulatory protocols, provide environments that are compliant with Good Manufacturing Practices and offer our clients' real-time monitoring and reporting. By outsourcing their logistics and transportation needs to AHG and our specialized services platform, our clients can focus on their core business.

While we believe the United States does not have as rigorous standards as Canada or Europe regarding the transportation of healthcare products, healthcare manufacturers are demanding high quality temperature control and monitoring as well as security and visibility for their truckload shipments in the United States, which aligns with our specialized transportation solutions. Both Boyle Transportation and Skelton USA comply with United States Pharmacopeia (USP) chapter <1079> Good Storage & Distribution Practices for Drug Products, to the extent applicable for transportation.

Boyle Transportation complies with U.S. Federal Motor Carrier Safety Administration regulations regarding the transportation of hazardous materials. Additionally, the National Industrial Security Program Operating Manual requires that Boyle Transportation be effectively insulated from any Foreign Ownership, Control, or Influence to perform on certain U.S. Department of Defense contracts and operates, under AHG's ownership, pursuant to a pending Special Security Agreement with the U.S. Defense Counterintelligence and Surveillance Agency.

### *Competition*

We believe that we offer a unique set of services in the marketplace and stand apart from other outsourced healthcare service providers and traditional logistics and transportation companies. In particular, we believe our differentiated capabilities, including our temperature management expertise, together with our coast-to-coast distribution network in Canada and multiple service offerings, uniquely positions us within our industry and sets us apart from companies specializing in global integration and supply chain management, national non-temperature managed solutions, regional temperature managed solutions as well as niche service providers and insourced transportation services. Notwithstanding the foregoing, we do compete with

UPS Supply Chain Solutions, Kuehne + Nagel and Lynden Logistics in our delivery of 3PL services, and with UPS, FedEx, Purolator, and several regional players in the specialized transportation space in Canada.

In the United States, Boyle Transportation and Skelton USA compete with a large number of regional carriers as well as national transportation providers, such as FedEx and CRST.

### *Acquisitions*

We selectively evaluate strategically compelling acquisition opportunities that leverage or expand our differentiated capabilities. In pursuing potential acquisition opportunities, we assess several criteria to expand our domestic platform, including: (i) complementary tuck-ins; and (ii) entry or expansion into growth verticals, new verticals and new service offerings. We will continue to assess opportunities for expansion in the U.S. or into international markets through existing platforms that align with our core capabilities and existing service offerings.

On October 5, 2020, we completed two tuck-in acquisitions: TDS Logistics Ltd. (“TDS”), now branded as “ATS Dedicated”, and McAllister Courier Inc. (“MCI”), our first acquisitions as a public company. These two regionally focused temperature-controlled transportation businesses increased the reach of our services and expanded our market presence in Ontario.

On March 1, 2021, we acquired 100% of Skelton Canada Inc. (“Skelton”) and 49% of Skelton USA Inc. (“Skelton USA” and together with Skelton, the “Skelton Companies”) which enhanced our platform with expanded national 2-8°C specialized temperature-controlled capabilities and provided us with a strategic entry into the U.S. market.

On November 1, 2021, we acquired 100% of T.F. Boyle Transportation, Inc. (“Boyle Transportation”), which provides specialized transportation services to clients in the life sciences and government/defense sectors, and the remaining 51% of Skelton USA, increasing our aggregate ownership of Skelton USA to 100%.

On March 1, 2022, we acquired 100% of Logistics Support Unit (LSU) Inc. (“LSU”). LSU is a third-party logistics provider offering specialty pharmacy, warehousing, distribution, and order management services throughout Canada to national and international companies as well as government clients in the pharmaceutical, medical, and biotechnology sectors.

### *Management & Employees*

Our employee culture is one of our fundamental strengths and a strategic priority. Our employees are passionate about our business and are dedicated to creating and improving solutions for our clients. We empower our employees through training and professional development programs and maintain open lines of communication that encourage our employees to suggest ways in which we can improve our operations. We recognize and celebrate employees who act as leaders within our team and promote movement within our organization in an effort to retain and encourage our top talent. As a result of this collaborative employee culture, we have fostered strong relationships with our employees across our operating segments, none of which are subject to collective bargaining agreements.

During Fiscal 2023 we implemented a new long-term incentive plan under our Omnibus Equity Incentive Plan dated December 11, 2019, for certain management members in order to further promote share ownership among our employees, ensure that employees can participate in the Company’s growth through its share price, and retain employees over the long-term.

## *Cost Management*

In order to provide the services that we offer, we incur various operating costs. These costs include amongst others, labour, rent, fuel, equipment, and insurance. We are susceptible to increases in the price of these items, many of which can fluctuate, often due to factors beyond our control, such as regional and global supply and demand dynamics, political events, global pandemics, terrorist activities, the strength of the Canadian dollar relative to other currencies, and natural disasters.

To mitigate the risk of cost escalation, we focus on operational excellence, synergies between our product lines and cost controls. We rely on, among other things, long-term planning, budgeting processes, and internal benchmarking to achieve our profitability targets. Additionally, we mitigate the risk of inflation by utilizing leases to finance our network of facilities, many of our vehicles and our logistics equipment, as well as by using third-party service providers. We also mitigate our exposure to rising fuel costs through the implementation of fuel surcharge programs, which pass the majority of cost increases to our clients. In addition, we have implemented a number of policies that focus on asset efficiency, including fuel economy, asset utilization, proper repairs and maintenance of equipment, and measured equipment lease renewals. Many of our contracts include cost escalation indexes that provide for annual price adjustments which further protect us from escalating costs.

## **Financial and Operational Highlights**

We refer the reader to the section entitled “How We Assess the Performance of Our Business” of this MD&A for the definition of the items discussed below and, when applicable, to the section entitled “Reconciliation of Non-IFRS Measures” for quantitative reconciliations of net income to EBITDA.

### *Q1 2024 Compared to Q1 2023*

Select highlights include the following:

- Revenue was \$161.1 million in Q1 2024, compared to \$164.8 million in Q1 2023;
- Operating income was \$21.2 million in Q1 2024, compared to \$23.7 million in Q1 2023;
- Net income was \$14.9 million in Q1 2024, compared to \$16.5 million in Q1 2023;
- Total comprehensive income for Q1 2024 was \$20.5 million, compared to \$16.3 million in Q1 2023;
- EBITDA was \$39.6 million in Q1 2024, compared to \$40.5 million in Q1 2023; and
- EBITDA Margin remained unchanged at 24.6% in Q1 2024 and in Q1 2023.

## How We Assess the Performance of Our Business

We have historically operated and managed our healthcare logistics and specialized transportation segments as separate businesses with separate management teams. Our healthcare logistics segment operates under the brand names Accuristix and LSU; and our specialized transportation segment operates under the brand names ATS Healthcare, ATS Dedicated, Boyle Transportation and Skelton Truck Lines. Following our initial public offering (“IPO”) completed December 11, 2019, both Accuristix and ATS Healthcare have continued to operate autonomously, each having its own management. Skelton, which we acquired on March 1, 2021, and Boyle Transportation and Skelton USA, which we acquired on November 1, 2021, which are reported in the specialized transportation segment, also operate autonomously, as they did prior to their respective acquisitions. Similarly, LSU, which we acquired on March 1, 2022, operates autonomously and is included in our healthcare logistics segment. Over time, as we grow, our operating segments may change. If this occurs, we will reflect the change in our reporting practices.

Except for tractors (with respect to periods prior to Q3 2023) and trailers purchased by Skelton and Boyle Transportation, our operating segments conduct their businesses in a manner that limits capital investments. We prefer to lease facilities and certain equipment rather than allocating significant cash flows to capital expenditures. We believe our business model provides us with greater flexibility, cost savings and lower risks, as compared to more capital expenditure intensive models. Accordingly, lease costs comprise a significant component of our expenses. Under IFRS 16 – Leases (“IFRS 16”), leases have been capitalized, resulting in the costs associated with our leases being recorded as depreciation and interest expense. We believe that the cash flows associated with our lease payments are a relevant metric in evaluating the performance of our business.

### *Revenue*

We generate revenue from the provision of supply chain solutions to the Canadian and United States healthcare sectors. Across our healthcare logistics and specialized transportation operating segments, we generate revenue across five principal product lines: logistics and distribution, packaging solutions, air freight forwarding, ground transportation, and dedicated and last mile delivery.

Our healthcare logistics segment, which offers services under our Accuristix and LSU brands, generates revenue from the provision of logistics and distribution services and packaging solutions to our clients. Services are typically provided under master service agreements with terms that range from three to five years in length. Our logistics contracts typically include a single performance obligation that is satisfied over time as clients simultaneously receive and consume the benefits of our services. For this performance obligation, we recognize revenue at the invoiced amount since this amount corresponds directly to our performance and the value to the client. In some cases, our agreements include other performance obligations related to managing transportation and other client services which are included in our logistics and distribution product line. These services are typically priced at their stand-alone selling prices and are recognized over time as the client simultaneously receives and consumes the benefits of our services. Intersegment revenue generated by Credo Systems Canada Inc. from the sale of thermal packaging containers to ATS Healthcare, as well as intra-segment revenue between Accuristix and Nova Pack Ltd. (“Nova Pack”) is eliminated on consolidation.

Our specialized transportation segment, which offers services under our ATS Healthcare, ATS Dedicated, Boyle Transportation and Skelton Truck Lines brands, generates revenue from the provision of specialized temperature-controlled, as well as non-temperature controlled, ground transportation, air freight forwarding and dedicated and last mile transportation services to our clients. Certain additional services are provided to clients as requested as part of their transportation contracts, such as chain of custody and other incidental services. Transportation revenue is recognized proportionally as a shipment moves from origin to destination

and the related costs are recognized as incurred. Performance obligations are short-term, with transit typically taking less than one week. Generally, clients are billed upon shipment of the freight, and remit payment according to approved payment terms. Intersegment revenue generated by ATS Healthcare and Skelton from the provision of transportation services to Accuristix and LSU, on behalf of their logistics clients, is eliminated on consolidation.

Our Boyle Transportation and Skelton USA subsidiaries provide specialized temperature-controlled services to healthcare companies in the United States, and, in the case of Boyle Transportation, to certain defense contractors and the U.S. Department of Defense. These companies, acquired in Fiscal 2021, align with our specialized transportation segment in all material respects except that they focus on full truckload ground transportation services, which traditionally realize lower margins than our ground transportation businesses in Canada.

As is customary in our industry, most of our client contracts and transportation pricing terms include fuel-surcharge revenue programs or cost recovery mechanisms to mitigate the effect of fuel price increases over base amounts established in the contract. However, these fuel surcharge mechanisms may not capture the entire amount of changes in fuel prices, and there is also a lag between the payment for fuel and collection of surcharge revenue. Increases or decreases in fuel prices increase or reduce the cost of transportation and services, and will accordingly increase or reduce our revenues and may reduce or increase margins for certain product lines. During Fiscal 2022 and Fiscal 2023, fluctuations in diesel fuel prices impacted both revenue and cost of transportation and services more significantly than in prior periods. Average diesel fuel prices in Q1 2024 were approximately 8% lower than in Q1 2023.

#### *Cost of Transportation and Services*

Our cost of transportation and services expense includes the cost of providing or procuring freight transportation to our clients. The cost of transportation and services for our specialized transportation segment includes: linehaul costs to connect our national network; pick-up and delivery costs paid to brokers, agents, and our drivers; fuel, toll fees and maintenance costs; and inbound and outbound handling costs which are largely comprised of hourly paid dock labour. The cost of transportation and services for our healthcare logistics segment includes purchased transportation services, including fuel surcharges, sourced from carriers. ATS Healthcare is the largest provider of transportation services to Accuristix and LSU, followed by Skelton. Intersegment purchased transportation expense is eliminated on consolidation.

#### *Direct Operating Expenses*

Direct operating expenses are both fixed and variable and consist of operating costs related to our facilities (including our distribution centres, branches and the cross-docks that we operate from). Direct operating expenses consist mainly of personnel costs and facility and equipment expenses such as property taxes, utilities, equipment maintenance and repair, costs of materials and supplies, security and insurance expenses. We note that under IFRS 16 the costs associated with our leases are not recognized in our direct operating expenses.

#### *Selling, General and Administrative Expenses*

Selling, General and Administrative (“SG&A”) expenses primarily consist of the cost of salaries and benefits for executive and certain administration functions, including information technology, sales and client service, finance and accounting, professional fees, facility costs, legal costs and other expenses related to the corporate infrastructure required to support our business.

### *Depreciation & Amortization*

Depreciation and amortization charges comprise non-cash charges expensed on the statement of income and comprehensive income to spread the purchase price of assets over their useful lives. Within both of our operating segments, we lease facilities and certain equipment rather than allocating significant cash flows to capital expenditures. We believe this approach provides us with greater flexibility and lower risks and results in cost savings as compared to capital expenditure intensive models. Accordingly, lease costs comprise a significant component of our expenses. Under IFRS 16, leases have been capitalized, resulting in depreciation and interest expense rather than direct operating expense.

### *Operating Income*

Operating Income measures the amount of profit derived from our operations after deducting operating expenses such as cost of transportation and services, direct operating expense, SG&A, and depreciation and amortization. We do not typically measure “cost of sales or gross profit” as we are a service business.

### *Interest Expense*

Interest expense comprises interest charged to the statement of income and comprehensive income primarily in connection with leased facilities and equipment under IFRS 16, and for borrowings under our Credit Facilities.

### *Interest Income*

Interest income comprises interest earned on cash and cash equivalents.

### *Other Income/Expense*

Other income (expense) comprises income or expenses that do not arise from our main business, such as exchange gains (losses) and gains (losses) resulting from the sale of property, plant and equipment and certain other insignificant sources.

### *Income Tax Expense/Recovery*

Income tax expense (recovery) comprises the amount that we have recognized in the accounting period related to our taxable income. Our effective tax rate is generally close to the statutory rate, but certain differences between income for tax and accounting income are recognized in the deferred income tax provision.

### *Foreign Currency Translation Adjustment*

In preparing our consolidated financial statements, the financial statements of each entity are translated into Canadian dollars. The assets and liabilities of foreign operations are translated to Canadian dollars at exchange rates as at the balance sheet date. Revenues and expenses of foreign operations are translated to Canadian dollars at exchange rates that approximate those on the date of the underlying transaction. Foreign exchange differences are recognized in other comprehensive income and accumulated in equity in accumulated other comprehensive income.

## *Non-IFRS Measures*

### EBITDA

We define EBITDA as net income for the period before: (i) income tax expense (recovery); (ii) interest income; (iii) interest expense; and (iv) depreciation and amortization. Net income is the most directly comparable IFRS financial measure disclosed in our financial statements to which EBITDA relates, and a reconciliation with this measure is presented under “Reconciliation of Non-IFRS Measures”.

We believe EBITDA is a useful measure to assess our financial performance because it provides a more relevant picture of operating results by excluding the effects of expenses that are not reflective of our underlying business performance.

### EBITDA Margin

We define EBITDA Margin as EBITDA divided by revenue. EBITDA Margin represents a measure of our profitability expressed as a percentage of revenue.

We believe EBITDA Margin is a useful measure to assess our financial performance because it helps quantify our ability to convert revenues generated from clients into EBITDA.

### **Selected Consolidated Financial Information**

The following table summarizes our results of operations for the periods indicated. The selected consolidated financial information for Q1 2024 and Q1 2023 has been derived from our unaudited interim condensed consolidated financial statements and the related notes thereto. See “Reconciliation of Non-IFRS Measures” for quantitative reconciliations of net income to EBITDA.

*Consolidated Statements of Income and Comprehensive Income*

(\$CAD 000s)	Three Months Ended March 31,	
	2024	2023
<b>Revenue</b>		
Logistics & distribution	37,918	40,523
Packaging solutions	4,942	5,510
Healthcare logistics segment	42,860	46,033
Ground transportation	106,388	108,260
Air freight forwarding	7,995	7,542
Dedicated and last mile delivery	17,745	17,131
Intersegment revenue	(13,850)	(14,192)
Specialized transportation segment	118,278	118,741
<b>Total revenue</b>	<b>161,138</b>	<b>164,774</b>
<b>Operating expenses</b>		
Cost of transportation and services	82,466	84,179
Direct operating expense	26,273	27,035
Selling, general and administrative expenses	12,816	13,110
Depreciation & amortization	18,340	16,760
	139,895	141,084
<b>Operating income</b>	<b>21,243</b>	<b>23,690</b>
Interest expense	(1,579)	(1,933)
Interest income	695	599
Other income (expense)	9	19
Income tax expense	(5,445)	(5,847)
<b>Net income</b>	<b>14,923</b>	<b>16,528</b>
<b>Other comprehensive income</b>		
Net income	14,923	16,528
Foreign currency translation adjustment	5,537	(200)
<b>Total comprehensive income</b>	<b>20,460</b>	<b>16,328</b>
<b>Earnings per share</b>		
Earnings per share – basic	\$ 0.36	\$ 0.39
Earnings per share – diluted	\$ 0.35	\$ 0.39
<b>Select financial metrics<sup>1</sup></b>		
EBITDA	39,592	40,469
EBITDA Margin	24.6%	24.6%

<sup>1</sup> These are non-IFRS financial measures. See “How We Assess the Performance of Our Business – Non-IFRS Measures” for further information on these measures.

### Consolidated Balance Sheets

(\$CAD 000s)	As At March 31,	
	2024	2023
<b>Select financial position data</b>		
Total assets	687,173	718,161
Total non-current liabilities	114,040	180,649

### Consolidated Statements of Changes in Equity

(\$CAD 000s)	Three Months Ended March 31,	
	2024	2023
<b>Select financial data</b>		
Dividends	4,132	3,353

### Reconciliation of Non-IFRS Measures

The following table provides a reconciliation of net income to EBITDA for Q1 2024 and Q1 2023:

(\$CAD 000s)	Three Months Ended March 31,	
	2024	2023
<b>Net income</b>	<b>14,923</b>	<b>16,528</b>
Income tax expense	5,445	5,847
Interest expense	1,579	1,933
Interest income	(695)	(599)
Depreciation and amortization	18,340	16,760
<b>EBITDA<sup>1</sup></b>	<b>39,592</b>	<b>40,469</b>

<sup>1</sup> This is a non-IFRS financial measure. See “How We Assess the Performance of Our Business – Non-IFRS Measures” for further information on this measure.

### Results of Operations

#### *Three months ended March 31, 2024 compared with 2023*

The following section provides an overview of our financial performance for Q1 2024 compared to Q1 2023.

#### Revenue

Revenue for Q1 2024 decreased by 2.2% to \$161.1 million, compared with \$164.8 million in Q1 2023. The decrease is primarily attributable to lower revenue in our US-based truckload businesses (Boyle Transportation and Skelton USA) and Accuristix, and lower fuel surcharge revenue, partially offset by growth in our Canadian specialized transportation products, excluding fuel surcharge revenue.

### *Healthcare Logistics Segment*

Revenue in our healthcare logistics segment for Q1 2024 was \$42.9 million, a decrease of 6.9%, or approximately \$3.2 million, compared with Q1 2023. The decrease in revenue for this segment was primarily driven by the factors set out below.

#### *Logistics & Distribution*

Logistics and distribution revenue for Q1 2024 was \$37.9 million, a decrease of 6.4%, or approximately \$2.6 million, compared with Q1 2023. The decrease was primarily attributable to lower outbound order handling and transportation activities for certain Accuristix consumer health clients.

#### *Packaging Solutions*

Packaging revenue for Q1 2024 was \$4.9 million, a decrease of 10.3%, or approximately \$0.6 million, compared with Q1 2023. The decline primarily reflects the loss of one of our packaging customers during Q1 2023.

### *Specialized Transportation Segment*

Revenue in our specialized transportation segment for Q1 2024 was \$118.3 million, a slight decrease of 0.4%, or approximately \$0.5 million, compared with Q1 2023. Revenue performance in this segment was primarily driven by the factors set out below.

#### *Ground Transportation*

Ground transportation revenue for Q1 2024 was \$106.4 million, a decrease of 1.7%, or approximately \$1.9 million, compared with Q1 2023. The decrease was primarily attributable to a decline in our US-based truckload business, reflecting lower rates and the Company's focus on revenue quality, as well as lower fuel costs passed through to customers as a component of pricing compared to Q1 2023. These factors were partially offset by organic growth in the Company's Canadian ground transportation network. Ground transportation revenue, excluding fuel, in the Company's Canadian network increased by approximately 3.2%.

#### *Air Freight Forwarding*

Air freight forwarding revenue for Q1 2024 was \$8.0 million, an increase of 6.0%, or approximately \$0.5 million, compared to Q1 2023, as our clients shipped approximately 2.3% more weight in Q1 2024 compared with Q1 2023.

#### *Dedicated and Last Mile Delivery*

Dedicated and last mile delivery revenue for Q1 2024 was \$17.7 million, an increase of 3.6%, or approximately \$0.6 million, compared with \$17.1 million for Q1 2023. The increase reflects organic growth, partially offset by a reduction in fuel surcharge revenue.

### Cost of Transportation and Services

Cost of transportation and services for Q1 2024 was \$82.5 million, or 51.2% of revenue, compared with \$84.2 million, or 51.1% of revenue, for Q1 2023. Lower fuel costs in line with decreases in revenue related to fuel prices were partially offset by idle equipment costs in our US-based truckload businesses arising from a lower volume of truckloads as we focused on revenue quality.

### Direct Operating Expenses

Direct operating expenses were \$26.3 million, or 16.3% of revenue, compared with \$27.0 million, or 16.4% of revenue, for Q1 2023. The decrease in direct operating expenses in Q1 2024 was attributable to a reduction in outbound order handling activities for Accuristix in line with lower revenue.

### Selling, General and Administrative Expenses

SG&A expenses for Q1 2024 were \$12.8 million, or 8.0% of revenue, compared with \$13.1 million, or 8.0% of revenue, for Q1 2023. Our SG&A expenses are in line with our expected operating ratio as a percentage of revenue.

### Depreciation and Amortization

Depreciation and amortization for Q1 2024 was \$18.3 million, an increase of 9.4% compared with \$16.8 million for Q1 2023. Approximately \$1.1 million of the increase was attributable to changes in the estimated useful lives and related depreciation methods of certain tangible assets arising from a reassessment of their expected usefulness to AHG and recent experience related to their economic lives. The changes in estimates have been made on a prospective basis. The full year impact of the changes in estimates is expected to result in a net reduction of depreciation expense attributable to these assets of \$0.9 million. The total amount of depreciation remains consistent as a percentage of our revenue at approximately 10% to 11%.

### Interest Expense

Interest expense for Q1 2024 was \$1.6 million compared with \$1.9 million for Q1 2023. Interest expense related to leased facilities and equipment comprises the majority of interest expense; however, \$0.4 million of interest expense for Q1 2024 was incurred in connection with our Credit Facilities, compared with \$0.8 million in Q1 2023. The decrease in interest expense related to our Credit Facilities was attributable to lower amounts drawn, partially offset by increased interest rates.

### Interest Income

Interest income for Q1 2024 was \$0.7 million compared with approximately \$0.6 million in Q1 2023. Interest income is generated on our cash and cash equivalents balances.

### Other Income

Other income was less than \$0.1 million for each of Q1 2024 and Q1 2023. These amounts vary from quarter to quarter and are not material to our overall performance for Q1 2024 and Q1 2023.

### Income Tax Expense

Income tax expense for Q1 2024 was \$5.4 million compared with \$5.8 million in Q1 2023. Our effective tax rate was close to the statutory rate of 26.5% for Q1 2024 and Q1 2023 after adjusting for non-deductible items such as share-based compensation expenses, taxes relating to previous years, and other negligible adjustments.

### Operating Income and Net Income

Operating income for Q1 2024 was \$21.2 million, a decrease of \$2.5 million, or 10.3%, compared with \$23.7 million for Q1 2023. The decrease in operating income was primarily attributable to lower contributions from our Boyle Transportation and Skelton USA operations, lower outbound order handling and transportation activities at Accuristix, and increased depreciation expense arising from the changes in estimated useful lives of certain tangible assets as described above.

Income before tax for the specialized transportation segment was \$16.4 million for Q1 2024 compared with \$17.1 million for Q1 2023. The decrease was primarily attributable to lower contributions from Boyle Transportation and Skelton USA, partially offset by increases from our Canadian specialized transportation businesses, and approximately \$0.8 million related to the changes in estimated useful lives of certain intangible assets as described above.

Income before tax for the healthcare logistics segment was \$3.9 million for Q1 2024 compared with \$5.1 million for Q1 2023. The decrease reflects reduced outbound order handling and transportation activities in line with the decrease in revenue for the period and approximately \$0.3 million related to the changes in estimated useful lives of certain intangible assets as described above.

Net income for Q1 2024 was \$14.9 million compared with \$16.5 million in Q1 2023. Lower segment net income before eliminations for our specialized transportation segment was primarily attributable to lower contributions from Boyle Transportation and Skelton USA; and lower segment net income from our healthcare logistics operating segment reflects reduced outbound order handling and transportation activities as discussed above. Both segments were impacted by increased depreciation expense arising from changes in estimated useful lives of certain tangible assets as described above.

### Foreign Currency Translation Adjustment

Foreign exchange differences of \$5.5 million and \$(0.2) million have been recognized in other comprehensive income for Q1 2024 and Q1 2023, respectively. These differences reflect assets and liabilities of Boyle Transportation and Skelton USA which have been translated to Canadian dollars at the exchange rates as at March 31, 2024 and 2023, respectively, and revenues and expenses which have been translated to Canadian dollars at exchange rates that approximate those on the date of the underlying transactions. Foreign exchange rates averaged approximately \$1.3488 during Q1 2024 and approximately \$1.3518 during Q1 2023.

### Total Comprehensive Income

Total comprehensive income was \$20.5 million for Q1 2024 compared to \$16.3 million for Q1 2023. Total comprehensive income differs from net income due to our foreign operations (Boyle Transportation and Skelton USA) resulting in foreign currency translation adjustments as described above.

### EBITDA

EBITDA for Q1 2024 was \$39.6 million compared with \$40.5 million for Q1 2023. The decrease was due to the factors discussed above and primarily reflects lower contributions from our US-based truckload businesses and reduced outbound order handling and transportation activities for Accuristix in line with lower revenue, partially offset by organic growth in our Canadian specialized transportation network. EBITDA attributable to Boyle Transportation and Skelton USA was approximately \$2.5 million lower in Q1 2024 compared to Q1 2023.

### EBITDA Margin

EBITDA Margin for Q1 2024 was 24.6% compared with 24.6% for Q1 2023. Lower margins in our US-based truckload businesses were effectively offset by organic growth in our Canadian specialized transportation network. The performance of our two operating segments continues to result in strong and industry-leading EBITDA Margins. The margin profiles of Boyle Transportation and Skelton USA, which were in line with our consolidated EBITDA range throughout Fiscal 2022 and into Q1 2023, have been impacted during Fiscal 2023 and Q1 2024 by post-pandemic macroeconomic factors, such as increased equipment and driver availability, resulting in fewer opportunities to obtain rate premiums. We believe that our US-based truckload rates and related margins returned to more normalized levels during Fiscal 2023, and we do not foresee a return to the premium levels we generated in Fiscal 2022, which may impact our comparative growth and margins in future periods.

### **Summary of Quarterly Results**

While there is no significant seasonality to our business, our results are impacted by our clients' storage and shipping activities throughout the year as well as the timing of new client implementations or exits.

The table below sets out our results for each of the eight most recently completed quarters (unaudited):

<b>(\$CAD 000s) except per share data</b>	<b>Q1-24</b>	<b>Q4-23</b>	<b>Q3-23</b>	<b>Q2-23</b>	<b>Q1-23</b>	<b>Q4-22</b>	<b>Q3-22</b>	<b>Q2-22</b>
Total revenue	161,138	169,067	156,754	157,357	164,774	165,772	164,898	169,402
Operating income	21,243	28,044	21,724	22,595	23,690	28,166	27,860	30,157
Net income	14,923	18,561	15,335	15,716	16,528	19,824	18,995	20,985
Total comprehensive income	20,460	13,540	20,147	10,677	16,328	17,052	32,902	27,560
EBITDA <sup>1</sup>	39,592	44,773	39,011	39,540	40,469	44,684	44,072	46,327
Earnings per share – basic	\$0.36	\$0.45	\$0.37	\$0.37	\$0.39	\$0.47	\$0.45	\$ 0.50
Earnings per share – diluted	\$0.35	\$0.44	\$0.36	\$0.37	\$0.39	\$0.46	\$0.44	\$ 0.49

<sup>1</sup> This is a non-IFRS financial measure. See “How We Assess the Performance of Our Business – Non-IFRS Measures” for further information on this measure.

Generally, changes in revenue generated through the past eight quarters reflect changes in shipping volumes from our clients, variable fuel surcharge rates, premium U.S. ground transportation rates in Fiscal 2022, and the impact of price increases which are contractually implemented in both of our operating segments annually or as contracts are renegotiated.

Several factors, described above, impacted lower revenue in Q2 2023 and Q3 2023 compared to the previous four quarters, including a decline in fuel surcharge revenues driven by lower diesel fuel prices, which are passed on to customers as a component of our pricing. Average fuel prices decreased by approximately 7% in Q1 2024 from Q4 2023, and were approximately 8% below levels experienced in Q1 2023. Average diesel fuel prices declined from Q2 2022 to Q3 2022, then increased from Q3 2022 to Q4 2022, remained relatively stable in Q4 2022, then increased again in Q1 2023 before declining in Q2 2023 and then increased again in Q3 2023 and Q4 2023.

Beginning in Fiscal 2021, we supported the distribution of COVID-19 vaccines and related products, such as test kits and personal protective equipment. Revenue related to COVID-19 declined as a percentage of our total revenue throughout Fiscal 2022 from approximately 5.5% in Q2 2022 to approximately 2.3% in Q4 2022 and declined to less than 1% in Fiscal 2023 and Q1 2024. We do not expect any appreciable revenue related to COVID-19 beyond Fiscal 2023.

Operating income, net income, comprehensive income, and EBITDA have continued to perform in line with revenue over the past eight quarters. Fiscal 2023 EBITDA margins in our US-based truckload businesses returned to more normalized, pre-pandemic levels and negatively impacted our consolidated margins in Fiscal 2023 relative to Fiscal 2022 by approximately 2.0%. Our EBITDA margin improved in Q4 2023 due to new business growth in our ATS Healthcare business. Our EBITDA margin in Q1 2024 remained unchanged compared to Q1 2023 reflecting the gains made in our ATS Healthcare business offset by lower margins in our US-based truckload businesses.

## **Liquidity & Capital Resources**

### *Overview*

Our principal uses of funds are for operating expenses, taxes, interest, capital expenditures, lease payments and dividends. We believe that cash generated from our operations, together with amounts available under our Credit Facilities will be sufficient to meet our future operating expenses, taxes, interest, capital expenditures, lease payments and any dividends that may be declared by our board of directors. However, our ability to fund operating expenses, taxes, interest, capital expenditures and future lease payments will depend on, among other things, our future operating performance, which will be affected by general economic, financial and other factors, including factors beyond our control. See “Accounting Classifications and Fair Values”, “Summary of Factors Affecting Performance” and “Risk Factors” in this MD&A. We review potential acquisitions and investment opportunities in the normal course of our business and may make select acquisitions and investments to implement our growth strategy when suitable opportunities arise.

Our tuck-in acquisitions of TDS and MCI in October 2020 for a purchase price of approximately \$15.9 million in cash were funded from existing cash flow from operations. We financed the acquisitions of Skelton and the initial 49% of Skelton USA in March 2021 through a combination of cash on hand and by drawing \$50.0 million on our Revolving Credit Facility and \$25.0 million on our Term Facility, and by issuing \$25.0 million of Subordinate Voting Shares to the shareholders of Skelton and Skelton USA. During Fiscal 2021, we repaid \$39.0 million of the \$50.0 million initially drawn on our Revolving Credit Facility in connection with the Skelton and Skelton USA acquisitions.

On November 1, 2021, we completed the acquisitions of 100% of Boyle Transportation and the remaining 51% of Skelton USA, increasing our aggregate ownership of Skelton USA to 100%. The aggregate purchase price for the acquisition of Boyle Transportation was approximately US\$83.0 million (\$104.7 million), of which approximately US\$63.0 million was paid in cash and US\$20.0 million was satisfied by issuing 522,116 Subordinate Voting Shares to the shareholders of Boyle Transportation. The aggregate purchase price for the acquisition of the remaining 51% interest in Skelton USA was approximately \$44.8 million, of which \$19.8 million was paid in cash and \$25.0 million was satisfied by issuing 518,672 Subordinate Voting Shares to the shareholders of Skelton USA. The cash portion of the purchase price for each acquisition was funded through the completion of a bought deal equity offering on October 26, 2021, pursuant to which AHG issued 2.0 million Subordinate Voting Shares from treasury for gross proceeds of \$96.4 million to the Company, with the remaining amounts funded from existing cash flow from operations.

On March 1, 2022, we acquired LSU for approximately \$26.7 million. We satisfied the purchase price through the issuance of 154,639 Subordinate Voting Shares to the shareholders of LSU and cash of approximately \$19.2 million comprising the cash portion of the purchase price net of provisional customary working capital adjustments. We financed the cash portion of the purchase price through a combination of cash on hand and by drawing on our Revolving Credit Facility. During Fiscal 2022, we repaid \$23.0 million of the amounts drawn on our Revolving Credit Facility in connection with the LSU and Skelton acquisitions. As at March 31, 2024, there was \$nil drawn on our Revolving Credit Facility.

During Fiscal 2023, cash from operating activities continued to build our cash and cash equivalents balance. On March 24, 2023, the Company announced a NCIB as described below. As of March 31, 2024, a total of 634,090 Subordinate Voting Shares, for a total of approximately \$25.1 million, have been purchased and cancelled pursuant to the NCIB. The NCIB terminated on March 28, 2024.

### *Working Capital*

The following table presents our working capital position as at March 31, 2024 and 2023:

(\$CAD 000s)	As at March 31,	
	2024	2023
Cash and cash equivalents	68,158	74,396
Trade and other receivables	100,251	101,336
Income taxes receivable	1,126	-
Inventories	5,313	3,590
Prepaid expenses and other	5,804	6,490
Due from related parties	108	57
Term facility	(24,856)	-
Accounts payable and accrued liabilities	(40,308)	(42,191)
Current portion of lease liabilities	(27,944)	(26,159)
Income taxes payable	-	(14,970)
<b>Working Capital</b>	<b>87,652</b>	<b>102,549</b>

As at March 31, 2024, we had working capital of \$87.7 million compared with working capital of \$102.5 million as at March 31, 2023. The \$14.9 million decrease in working capital is primarily attributable to the classification of our Term Facility, as described below, in current liabilities offset by ordinary fluctuations in working capital and a receivable balance for income taxes arising from tax installments remitted based on Fiscal 2022 earnings.

### *Credit Facilities*

We entered into credit facilities upon closing of our IPO, comprised of a revolving credit facility (the “Revolving Credit Facility”) in the aggregate principal amount of up to \$75.0 million and a term facility (the “Term Facility”, and together with the Revolving Credit Facility, the “Credit Facilities”) in the aggregate principal amount of up to \$25.0 million. On February 19, 2021, in connection with our acquisitions of Skelton and 49% of Skelton USA, we amended our Credit Facilities to increase the amounts available to be drawn under the Revolving Credit Facility and the Term Facility each by \$25.0 million. The amended Credit Facilities comprise a Revolving Credit Facility in the aggregate principal amount of up to \$100.0 million and a Term Facility in the aggregate principal amount of up to \$50.0 million. The remaining terms and conditions of the Credit Facilities remain unchanged, except that they will mature and be due and payable on March 1, 2025. As the Term Facility is payable on March 1, it has been classified as a current liability on our balance sheet as at March 31, 2024. As at March 31, 2024, the aggregate amount outstanding before financing costs under the Credit Facilities was \$25.0 million under the Term Facility and \$nil under the Revolving Credit Facility.

The Revolving Credit Facility is available to be drawn in Canadian dollars by way of prime rate loans, bankers’ acceptances and letters of credit, and in U.S. dollars by way of base rate loans and letters of credit, in each case, plus the applicable margin in effect from time to time. The Term Facility was drawn in a single Canadian dollar advance of \$25.0 million on closing of the IPO by way of prime rate loans and was subsequently converted to bankers’ acceptances and increased by a single Canadian dollar advance of \$25.0 million by way of bankers’ acceptances in connection with the Skelton acquisitions on March 1, 2021.

The Credit Facilities are subject to customary negative covenants and include financial covenants requiring us to maintain at all times a maximum net leverage ratio and a minimum interest coverage ratio, tested on a quarterly basis. As at March 31, 2024, we were in compliance with all of the covenants under the Credit Facilities.

In order to support future potential growth through acquisitions, the Credit Facilities also include an accordion feature to allow us to increase the commitment under one or both of the Credit Facilities in an aggregate principal amount of up to \$100.0 million, such that any amounts drawn under the accordion feature would be in addition to the amounts ordinarily available, subject to the agreement of participating lenders and provided that we are not, or would not, be in default under the Credit Facilities, or in non-compliance with any financial covenants and an event of default does not or would not exist, after giving effect thereto and provided that all representations and warranties are true and correct immediately prior to, and after giving effect to, such increase. As of the date of this MD&A, this accordion feature remains uncommitted.

As of the date of this MD&A, we are in discussions with members of our lending syndicate to amend or extend our Credit Facilities beyond their maturity on March 1, 2025.

### *Capital Expenditures*

Capital expenditures for Q1 2024 were \$8.0 million, compared with \$5.2 million for Q1 2023. Capital expenditures have historically been funded through cash flows from operations. We have traditionally divided our capital expenditures into two subcategories, maintenance capital expenditures and growth capital expenditures, which are discussed further below.

The Company will generally seek to lease trucks and tractors for the foreseeable future to ensure that its fleet continues to run the most fuel efficient and latest diesel engines; and will generally seek to purchase trailers to ensure that their underlying useful lives are maximized.

### *Maintenance Capital Expenditures*

Maintenance capital expenditures refers to capital expenditures necessary for us to sustain our assets in order to continue operating in our current form. We generally seek to maintain our facilities and equipment at a level consistent with the needs of the sector we operate within and ensure that preventative maintenance programs are in place to achieve the performance expected from our facilities and equipment. Outlays for maintenance capital expenditures for Q1 2024 were \$7.6 million, compared with \$1.0 for Q1 2023. These capital expenditures were funded through cash flows from operations and are largely comprised of expenditures relating to purchases of specialized trailers for ATS Healthcare, Skelton, and Boyle Transportation and specialized Crêdo<sup>®</sup> packaging to maintain ATS Healthcare's specialized packaging rental program.

### *Growth Capital Expenditures*

Growth capital expenditures comprise expenditures on new assets that are intended to grow our productive capacity. These capital expenditures are made to acquire or expand leasehold improvements, transportation and logistics equipment (including pick-up and delivery equipment, warehouse racking, material handling equipment, warehouse automation equipment and specialized logistics equipment such as coolers or vaults, among others), furniture and fixtures, and computer equipment to support new contracts or additional volume from new business. Outlays for growth capital expenditures for Q1 2024 were \$0.4 million compared with \$4.2 million in Q1 2023.

Growth capital expenditures can range from \$5.0 million to over \$15.0 million in any given fiscal year, depending on the underlying expansion need. Growth capital expenditures have also historically been funded through cash flows from operations. Growth capital expenditures for Q1 2024 were primarily attributable to a cooler expansion in our Accuristix Calgary facility. Growth capital expenditures for Q1 2023 were primarily attributable to the purchase of trailers for Skelton and Boyle and warehouse equipment for LSU.

We are implementing the Tecsys Itopia<sup>®</sup> platform, a healthcare logistics 'software as a service' platform, to replace our prior warehouse management system ("WMS"). Tecsys Inc. ("Tecsys") is a supply chain management software company, and its technology stack will provide us with updated warehouse management and transportation management capabilities as well as end-to-end analytics and business intelligence. Our first client went live on our new WMS in Q1 2023. Implementations continued throughout Fiscal 2023 and will continue throughout Fiscal 2024 and Fiscal 2025. Our new WMS implementation has extended beyond our original project timeline due, in part, to delays in the delivery of required 3PL functionality in the base application code. We are working closely with Tecsys to address our functionality requirements. We expect the implementation will be complete by the end of Fiscal 2025. In Q1 2024, we capitalized \$0.3 million to intangible assets in connection with our new WMS.

## Cash Flows

The following table presents cash flows for the three months and year ended March 31, 2024 and 2023:

(\$CAD 000s)	Three Months Ended March 31,	
	2024	2023
<b>Cash flows</b>		
Cash from Operating Activities	33,196	24,396
Cash (used in) Financing Activities	(17,409)	(10,488)
Cash (used in) Investing Activities	(8,029)	(5,340)
Effect of foreign currency translation <sup>1</sup>	660	(27)
<b>Net change in cash</b>	<b>8,418</b>	<b>8,541</b>
<b>Select cash flow data</b>		
Capital expenditures	(7,978)	(5,209)
Lease payments	(8,347)	(8,309)

<sup>1</sup> Comprises the effect of differences in exchange rates for U.S. dollar opening balance sheet cash balances on January 1, 2024 and 2023 versus March 31, 2024 and 2023 for Boyle Transportation and Skelton USA.

### *Cash Flow Generated From Operating Activities*

Cash flow generated from operating activities for Q1 2024 totaled \$33.2 million compared with \$24.4 million for Q1 2023. The increase in cash flows generated from operating activities relates principally to normal fluctuations in trade accounts receivable, trade accounts payable and other working capital balances. During Fiscal 2023 we made income tax installments based on Fiscal 2022 income taxes, resulting in an over installment of income taxes for Fiscal 2023 due to reduced operating income from our US-based truckload businesses. Accordingly, the Company has \$1.1 million of income taxes receivable as at March 31, 2024.

### *Cash Flow Used In Financing Activities*

Cash flow used in financing activities for Q1 2024 totaled \$17.4 million compared with \$10.5 million for Q1 2023. The increase was primarily attributable to our purchase of 159,350 Subordinate Voting Shares for \$6.3 million pursuant to our NCIB as described below. The remaining cash flows used in financing activities in Q1 2024 and Q1 2023 relate to ordinary course repayments of lease liabilities and dividends. In Q1 2024, we increased our quarterly dividend to \$0.10 (from \$0.09) per Subordinate Voting Share and Multiple Voting Share, respectively.

### *Cash Flow Used In Investing Activities*

Cash flow used in investing activities for Q1 2024 totaled \$8.0 million compared with \$5.3 million for Q1 2023. The increase was primarily attributable to normal course expenditures on property, plant and equipment.

## Contractual Obligations

As at December 31, 2023, we had the following contractual commitments:

- Outstanding letters of guarantee in the amount of \$0.4 million (March 31, 2023 – \$0.4 million);
- Commitments relating to the leasing of fleet equipment, ranging from 72 to 84 months, beginning upon delivery to us of the equipment in Q2 2024, for total lease commitments of \$13.4 million (March 31, 2023 – \$10.5 million); and
- Commitments to purchase fleet equipment expected to be delivered during Fiscal 2024 totaling \$2.4 million (March 31, 2023 – \$14.3 million).

### *Credit facilities*

As at March 31, 2024, the aggregate amounts outstanding under the Credit Facilities were \$25.0 million under the Term Facility (March 31, 2023 – \$50.0 million) and \$nil under the Revolving Credit Facility (March 31, 2023 – \$nil) before capitalized financing costs. The Credit Facilities will mature and be due and payable on March 1, 2025 and have, accordingly, been classified under current liabilities on our balance sheet as at March 31, 2024.

### *Leases*

We lease buildings and equipment in the operation of our healthcare logistics and specialized transportation operating segments. Building lease terms range from five to ten years, with many leases including optional extension periods. For Q1 2024, facility lease liabilities are calculated using our average incremental borrowing rate of 5.55% (Q1 2023 – 5.44%). Equipment lease terms range from one to seven years. For Q1 2024, equipment lease liabilities are calculated using our average incremental borrowing rate of 5.70% (Q1 2023 – 5.45%) for our specialized transportation segment and 5.74% (Q1 2023 – 5.80%) for our healthcare logistics segment.

The following table summarizes our contractual obligations as at March 31, 2024 based on undiscounted cash flows:

(\$CAD 000s)				
	Total	Less than 1 Year	1-5 Years	More than 5 years
Credit facilities	25,000	25,000	-	-
Lease liabilities	109,280	30,992	74,413	3,875
Equipment purchases and lease commitments	15,845	4,437	11,408	-
Other obligations	82,038	40,308	41,730	-
<b>Total contractual obligations</b>	<b>232,163</b>	<b>100,737</b>	<b>127,551</b>	<b>3,875</b>

## Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have, or are reasonably expected to have, a current or future material impact on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

## Seasonality

There is no significant seasonality to our business.

## Financial Instruments

### *Financial assets*

Accounts receivable are initially recognized when they are originated. All other financial assets and financial liabilities are initially recognized when we become a party to the contractual provisions of the instrument.

A financial asset (unless it is an account receivable without a significant financing component) or financial liability is initially measured at fair value plus, for an item not at fair value through profit and loss, transaction costs that are directly attributable to its acquisition or issue. An account receivable without a significant financing component is initially measured at the transaction price.

Our financial assets are comprised of cash and cash equivalents, accounts receivable, and long-term deposits. On initial recognition, we classify these financial assets as measured at amortized cost, when both of the following conditions are met:

- it is held within a business model whose objective is to hold assets to collect contractual cash flows; and
- its contractual terms give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

These financial assets are subsequently measured at amortized cost using the effective interest method. The amortized cost is reduced by impairment losses. Interest income, foreign exchange gains and losses and impairment are recognized in profit or loss. Any gain or loss on de-recognition is recognized in profit or loss.

### *Impairment of financial assets*

Financial assets are assessed for indicators of impairment at the end of each reporting period. Financial assets are considered to be impaired when there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows of the investment have been decreased.

For accounts receivable, we apply a simplified approach in calculating expected credit losses (“ECLs”). Therefore, we do not track changes in credit risk but instead recognize a loss allowance based on lifetime ECLs at each reporting date. We have established a provision matrix that is based on our historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

When an account receivable is considered uncollectible, it is written off against the allowance account. Subsequent recoveries of amounts previously written off are offset against the allowance account. Changes in the carrying amount of the allowance account are recognized in profit or loss.

### *Financial liabilities*

Our financial liabilities are comprised of accounts payable and accrued liabilities, lease liabilities, income taxes payable and amounts due from related parties. Our financial liabilities are measured at amortized cost using the effective interest method. Interest expense and foreign exchange gains and losses are recognized in profit or loss. Any gain or loss on de-recognition is also recognized in profit or loss.

### *Foreign exchange contracts*

The Company, from time to time, uses foreign exchange contracts to manage certain exposures to fluctuations in foreign exchange rates as part of its overall risk management program. Earnings impacts from derivatives used to manage a particular risk are reported as part of other comprehensive income.

There were no foreign exchange contracts in place during Q1 2024 or as at March 31, 2024.

### **Related Party Transactions**

Intercompany balances and transactions have been eliminated in our unaudited interim condensed consolidated financial statements for the three-month periods ended March 31, 2024 and 2023.

During Q1 2024 and Q1 2023, we entered into transactions with related parties that were incurred in the normal course of business. Our policy is to conduct all transactions and settle all balances with related parties at market terms and conditions. All outstanding balances with these related parties are measured at amortized cost and are to be settled in cash within two months of the reporting date. None of the balances are secured. No expense has been recognized in the current year or prior year for bad or doubtful debts in respect of amounts owed by related parties.

Certain of our operating units provide services to other operating units outside of their reportable segment. Billings for such services are based on negotiated rates, which approximate fair value, and are reflected as revenues of the billing segment. These rates are adjusted from time to time based on market conditions. Such intersegment revenues and expenses are eliminated in our consolidated results. Michael Andlauer, our Chief Executive Officer (“CEO”), is also our Chief Operating Decision Maker (“CODM”). The CODM regularly reviews financial information at the operating segment level in order to make decisions about resources to be allocated to the segments and to assess their performance. Segment results that are reported to the CODM include items directly attributable to a segment, as well as those that can be allocated on a reasonable basis. We evaluate performance based on the various financial measures of our two operating segments.

The amounts below are expressed in thousands of Canadian dollars, unless otherwise specified.

### *Andlauer Management Group Inc.*

As of the date hereof, Andlauer Management Group Inc. (“AMG”) holds all of the Multiple Voting Shares of the Company (the “Multiple Voting Shares” and, together with the Subordinate Voting Shares, the “Shares”) and 10,200 Subordinate Voting Shares, representing approximately 52.9% of the issued and outstanding Shares and 81.8% of the voting power attached to all of the Shares. AMG is owned and controlled by Michael Andlauer, our CEO and a director of the Company.

We undertake a limited amount of administrative shared services for AMG. We expect to continue to incur and recover such costs in connection with AMG. For Q1 2024, we charged AMG \$nil (Q1 2023 – \$4) for recovery of shared services costs.

#### *Andlauer Properties and Leasing Inc.*

Andlauer Properties and Leasing Inc. (“APLI”) is a subsidiary of AMG and leases certain facilities and logistics and transportation equipment to us. We also lease facilities and logistics and transportation equipment from arm’s length providers. During Q1 2024, we paid \$642 (Q1 2023 - \$500) for leases of logistics and transportation equipment; and \$547 (Q1 2023 - \$588) for leases of facilities from APLI. The specific facilities that we lease from APLI are located at: 881 Bell Blvd. W, Belleville, Ontario; 18 Sandbourne Dr., Pontypool, Ontario; 80 – 14th Avenue, Hanover, Ontario; 465 Ofield Road South, Dundas, Ontario; 605 Max Brose Drive, London, Ontario; and 5480 61 Avenue SE, Calgary, Alberta. We expect to continue leasing properties and equipment from APLI. For Q1 2024, we charged APLI \$nil (Q1 2023 - \$5) for recovery of shared services costs.

#### *9143-5271 Québec Inc.*

9143-5271 Québec Inc. is a subsidiary of AMG and leases a facility located at 655 Desserte E. Hwy 13, Laval, Québec to AHG. We also lease facilities from arm’s length providers. During Q1 2024, we paid \$387 (Q1 2023 - \$383) for this building. We expect to continue leasing this property. For Q1 2024, we charged 9143-5271 Québec Inc. \$nil (Q1 2023 - \$8) for recovery of shared services costs.

#### *Ready Staffing Solutions Inc.*

Ready Staffing Solutions Inc. (“RSS”), a company owned by Mr. Andlauer’s spouse, provides us with temporary agency employee services – providing hourly dock labour for our handling operations, principally in the Greater Toronto Area. We also purchase temporary agency employee services from arm’s length providers. During Q1 2024, we expensed \$1,547 (Q1 2023 - \$1,693) for purchases of temporary agency employee services from RSS. We expect to continue purchasing temporary agency services from RSS.

#### *1708998 Ontario Limited (Medical Courier Services)*

Medical Courier Services (“MCS”) is a subsidiary owned 80% by AMG and provides transportation services to us, providing extended reach for shipments where we do not have our own facilities or equipment. During Q1 2024, we expensed \$52 (Q1 2023 - \$44) for deliveries subcontracted to MCS. We expect to continue subcontracting deliveries to MCS. Similarly, in Q1 2024 we invoiced MCS for \$51 (Q1 2023 - \$56) for transportation services provided to MCS. For Q1 2024, we charged MCS \$nil (Q1 2023 - \$6) for recovery of shared services costs.

#### *Med Express Ltd.*

Med Express Ltd. (“MEL”) is a subsidiary owned 100% by AMG. MEL provides transportation services to AHG, providing extended reach for shipments where we do not have our own facilities or equipment. We purchased \$nil in services during Q1 2024 (Q1 2023 - \$10). We expect to continue to subcontract deliveries to MEL from time to time.

#### *Key Management Personnel*

Our key management personnel, and persons connected with them, are also considered to be related parties for disclosure purposes. Key management personnel are defined as those individuals having authority and responsibility for planning, directing and controlling the activities of the Company and include our CEO, the other four named executive officers comprising key management and the board of directors.

During Q1 2024, we recorded \$1,269 (Q1 2023 – \$1,214) related to key management personnel salaries and benefits, share-based compensation, and director fees.

### *Due from/to related parties*

The charts below summarize amounts due to or from related parties.

(\$CAD 000s)	As at March 31,	
	2024	2023
<b>Accounts receivable</b>		
Andlauer Properties and Leasing Inc.	13	13
1708998 Ontario Limited (Medical Courier Services)	19	21
Trade receivables due from related parties	32	34
<b>Due from related parties</b>		
Andlauer Management Group Inc.	8	57
Andlauer Properties and Leasing Inc.	100	-
Due from related parties	108	57
<b>Total due from related parties</b>	<b>140</b>	<b>91</b>
<b>Accounts payable and accrued liabilities</b>		
Ready Staffing Solutions Inc.	399	286
1708998 Ontario Limited (Medical Courier Services)	31	-
Andlauer Properties and Leasing Inc.	79	105
Andlauer Management Group Inc.	9	4
Trade payables due to related parties	518	395
<b>Due to related parties</b>		
Andlauer Properties and Leasing Inc.	325	384
Due to related parties	325	384
<b>Total due to related parties</b>	<b>843</b>	<b>779</b>

### **Critical Accounting Judgements and Estimates**

The preparation of our consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions about future events. These estimates and the underlying assumptions affect the reported amounts of assets and liabilities, the disclosures about contingent assets and liabilities, and the reported amounts of revenues and expenses and apply equally to both our healthcare logistics segment and our specialized transportation segment. Such estimates include the expected credit losses on accounts receivable, the useful life of long-lived assets, our incremental borrowing rate, valuation of property, plant and equipment, valuation of goodwill and intangible assets, the measurement of identified assets and liabilities acquired in business combinations, share-based compensation arrangements, the provision for income taxes and other provisions and contingencies. These estimates and assumptions are based on management's best estimates and judgments. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. Management adjusts such estimates and assumptions when facts and circumstances dictate. Actual results could differ from these estimates. Changes in those estimates and assumptions resulting from changes in the economic environment will be reflected in the consolidated financial statements of future periods. Information about critical judgments, assumptions and estimation uncertainties that have a significant risk of resulting in a material adjustment within the next financial year have been described in our consolidated financial statements for the years ended

December 31, 2023 and 2022. Key estimates and assumptions remain consistent with those disclosed in our consolidated financial statements, except for changes in the estimated useful lives of certain property, plant and equipment as described below.

Effective January 1, 2024, the Company revised the estimated useful lives and related depreciation methods of certain tangible assets reflecting a reassessment of their expected usefulness to the Company, and recent experience related to their economic lives. The changes in estimates have been made on a prospective basis. For the three months ended March 31, 2024, the changes in estimates increased depreciation expense by approximately \$1.1 million. The full year impact of the changes in estimates is expected to result in a net reduction of depreciation expense of approximately \$0.9 million.

## **Significant New Accounting Standards**

### *Adopted During the Period*

There were no new standards that became effective for periods beginning on or after January 1, 2024 that had a material impact on our unaudited interim condensed consolidated financial statements for Q1 2024.

### *To be Adopted in Future Periods*

On March 13, 2024, the Canadian Sustainability Standards Board (“CSSB”) announced the release of its first proposed Canadian Sustainability Disclosure Standards (“CSDS”) – CSDS 1 and CSDS 2. The proposed standards generally align with the International Sustainability Standards Board’s IFRS S1, General Requirements for Disclosure of Sustainability-related Financial Information, and IFRS S2, Climate-related Disclosures, except that they include Canadian-specific effective dates and transition relief proposals to help with eventual implementation of the standards. The proposed standards are voluntary and are effective January 1, 2025. We will monitor the CSSB standards as they develop to ensure we are prepared to comply with them as they become effective.

During Fiscal 2023, we developed corporate-wide environmental, social and governance (“ESG”) performance metrics and disclosures that align with the Sustainable Accounting Standard Board standards (now part of the IFRS Foundation) for our industry, Road Transportation and Logistics, to help us prepare for future ESG disclosures and measure performance improvements from implementing action plans. We also filed our initial report of greenhouse gas emissions for Fiscal 2022 on the CDP portal. We expect to continue to report our climate progress annually to our clients and key stakeholders via the CDP Supply Chain Climate Change disclosures.

We are committed to the well-being of the many communities in which we serve and believe environmentally sustainable and socially responsible business practices and good governance will add value for all stakeholders. Our inaugural Sustainability Report has been filed concurrently with this MD&A and can be found on our profile on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca) or on our website at [www.andlauerhealthcare.com](http://www.andlauerhealthcare.com).

## **Accounting Classifications and Fair Values**

Our financial instruments consist of cash and cash equivalents, accounts receivable, deposits, and accounts payable and accrued liabilities. We believe that the carrying amount of each of these items is a reasonable approximation of fair value.

## **Risk Factors**

For a detailed description of risk factors associated with the Company, refer to the “Risk Factors” section of our AIF, which is available on the Company’s profile on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca).

### *Credit Risk*

We are exposed to credit risk in the event of non-performance by counterparties in connection with our financial assets, namely cash and cash equivalents, accounts receivable and long-term deposits. We do not typically obtain collateral or other security to support the accounts receivable subject to credit risk but mitigate this risk by performing credit check procedures for new clients and monitoring credit limits for existing clients. Thereby, we deal only with what management believes to be financially sound counterparties and, accordingly, do not anticipate significant loss for non-performance.

The maximum exposure to credit risk for cash and cash equivalents, accounts receivable and long-term deposits approximate the amount recorded on the consolidated balance sheets.

### *Liquidity Risk*

Liquidity risk is the risk that we will encounter difficulty in meeting the obligations associated with our financial liabilities that are settled by delivering cash or another financial asset. Our approach to managing liquidity is to ensure, as far as possible, that we will have sufficient liquidity to meet our liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to our reputation.

Our exposure to liquidity risk is dependent on the collection of accounts receivable, or raising of funds to meet commitments and sustain operations. We control liquidity risk by management of working capital, cash flows and the availability of borrowing facilities.

We have entered into Credit Facilities with affiliates of RBC, CIBC, and The Bank of Nova Scotia, comprised of a Revolving Credit Facility in the aggregate principal amount of up to \$100.0 million and a Term Facility in the aggregate principal amount of up to \$50.0 million. The Credit Facilities are available to be drawn in Canadian dollars by way of prime rate loans, bankers’ acceptances and letters of credit, and in U.S. dollars by way of base rate loans and letters of credit, in each case, plus the applicable margin in effect from time to time. In order to support future potential growth through acquisitions, the Credit Facilities also include an accordion feature to allow us to increase the commitment under one or both of the Credit Facilities in an aggregate principal amount of up to \$100.0 million, such that any amounts drawn under the accordion feature would be in addition to the amounts ordinarily available, subject to the agreement of participating lenders and provided that we are not, or would not, be in default under the Credit Facilities or in non-compliance with any financial covenants and an event of default does not or would not exist, after giving effect thereto and provided that all representations and warranties are true and correct immediately prior to, and after giving effect to, such increase. As at March 31, 2024, the aggregate amounts outstanding under the Credit Facilities were \$25.0 million under the Term Facility and \$nil under the Revolving Credit Facility before capitalized financing costs. As of the date of this MD&A, this accordion feature remains uncommitted.

Our accounts payable and accrued liabilities are due and payable in the short term. Our Term Facility has been classified as a current liability as it is payable on March 1, 2025.

### *Interest Rate Risk*

We have a Revolving Credit Facility and Term Facility that each bear interest at a floating rate subject to fluctuations in interest rates. Changes in interest rates can cause fluctuations in interest payments and cash flows. We do not use derivative financial instruments to mitigate the effect of this risk. The Credit Facilities are available to be drawn in Canadian dollars by way of prime rate loans, bankers' acceptances and letters of credit, and in U.S. dollars by way of base rate loans and letters of credit, in each case, plus the applicable margin in effect from time to time. At March 31, 2024, the Credit Facilities comprise bankers' acceptances drawn at an interest rate of 6.7%. There has been no significant impact on our financial condition or results of operations related to interest rates. There may be further increases in interest rates in the near term as the Governing Council of the Bank of Canada continues to target 2-3% inflation, however we expect that any such increases will not significantly impact our financial condition.

### *Currency Risk*

We enter into foreign currency purchase and sale transactions and have assets and liabilities that are denominated in foreign currencies and thus are exposed to the financial risk of earnings fluctuations arising from changes in foreign exchange rates and the degree of volatility of these rates. We use derivative instruments to reduce our exposure to foreign currency risk only where appropriate. During Q1 2024 and as at March 31, 2024 there were no derivative instruments in place.

### **Outstanding Share Data**

Our authorized share capital consists of an unlimited number of Subordinate Voting Shares, an unlimited number of Multiple Voting Shares and an unlimited number of preferred shares, issuable in series. As at May 2, 2024, there were 19,483,920 Subordinate Voting Shares issued and outstanding, 21,840,000 Multiple Voting Shares issued and outstanding (each of which is convertible into Subordinate Voting Shares on a one-for-one basis), and no preferred shares issued and outstanding. In addition, as at March 2, 2024 we had 1,078,556 options, each of which can be exercised or settled for one Subordinate Voting Share, 30,170 Restricted Share Units and 59,738 Deferred Share Units issued and outstanding under our omnibus incentive plan. As of the date hereof, AMG holds all of the Multiple Voting Shares and 10,200 of the Subordinate Voting Shares, representing approximately 52.9% of the issued and outstanding Shares and 81.8% of the voting power attached to all of the Shares.

On March 24, 2023, the Company announced that the TSX had approved its notice of intention to make a normal course issuer bid ("NCIB") for up to a maximum of 1,856,857 of its Subordinate Voting Shares, or approximately 10% of its public float as of March 23, 2023, over the 12-month period which commenced on March 29, 2023. In total, we purchased and cancelled a total of 634,090 Subordinate Voting Shares, or approximately 3% of our public float, pursuant to the NCIB. We funded the purchases, which totaled \$25.1 million, out of available cash. The NCIB terminated on March 28, 2024.

Subject to financial results, capital requirements, available cash flow, corporate law requirements and any other factors that our board of directors may consider relevant, we expect to declare a quarterly dividend on the Subordinate Voting Shares and Multiple Voting Shares equal to approximately \$0.10 per share on an ongoing basis. Our Q1 2024 dividend, in the amount of \$0.10 per Share, was paid on April 15, 2024 to shareholders of record as at March 28, 2024. Dividends are declared and paid in arrears. The amount and timing of the payment of any dividends are not guaranteed and are subject to the discretion of our board of directors.

## Disclosure Controls and Procedures and Internal Controls Over Financial Reporting

In compliance with the provisions of National Instrument 52-109 – *Certification of Disclosure in Issuers' Annual and Interim Filings*, we have filed certificates signed by our CEO and by our Chief Financial Officer (“CFO”) that, among other things, report on:

- their responsibility for establishing and maintaining disclosure controls and procedures (“DC&P”) and internal control over financial reporting (“ICFR”) for the Company; and
- the design and effectiveness of DC&P and the design and effectiveness of ICFR.

Management, including our CEO and CFO, does not expect that the disclosure controls or internal controls over financial reporting of the Company will prevent or detect all errors and all fraud or will be effective under all potential future conditions. A control system is subject to inherent limitations and, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control systems objectives will be met.

Further, the design of a control system must reflect that there are resource constraints, and the benefits of controls must be considered relative to their costs. Inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Controls can also be circumvented by individual acts of some persons, by collusion of two or more people or by management override of the controls. Due to the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. The design of any control system is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential conditions. Projections of any evaluations of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### *Disclosure Controls and Procedures*

The CEO and the CFO, have designed DC&P, or have caused them to be designed under their supervision, in order to provide reasonable assurance that:

- material information relating to AHG is made known to the CEO and CFO by others, particularly during the period in which the interim and annual filings are being prepared; and
- information required to be disclosed by AHG in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation.

### *Internal Controls Over Financial Reporting*

The CEO and CFO have also designed ICFR, or have caused them to be designed under their supervision, in order to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS.

The control framework used to design our ICFR is based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) on Internal Control – Integrated Framework (2013 framework).

### *Changes in Internal Controls Over Financial Reporting*

No changes were made to our ICFR during Q1 2024 that have materially affected, or are reasonably likely to materially affect, our ICFR.

### **Additional Information**

Additional information about AHG, including our AIF, can be found on our profile on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca) or on our website at [www.andlauerhealthcare.com](http://www.andlauerhealthcare.com).



Unaudited Interim Condensed Consolidated  
Financial Statements of

**ANDLAUER HEALTHCARE  
GROUP INC.**

For the three months ended March 31, 2024 and 2023

# Andlauer Healthcare Group Inc.

## Interim Condensed Consolidated Balance Sheets

As at March 31, 2024 and December 31, 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

		March 31, 2024	December 31, 2023
<b>Assets</b>	<b>Note</b>		
Current assets			
Cash and cash equivalents		\$ 68,158	\$ 59,740
Trade and other receivables		100,251	102,206
Income taxes receivable		1,126	1,230
Inventories		5,313	5,329
Prepaid expenses and other		5,804	6,605
Due from related parties	16	108	1
		<u>180,760</u>	<u>175,111</u>
Non-current assets			
Long-term deposits and other		974	911
Property, plant and equipment	4	165,402	166,200
Goodwill and intangible assets	5	334,923	334,919
Deferred income taxes	12	5,114	5,285
		<u></u>	<u></u>
<b>Total Assets</b>		<b>\$ 687,173</b>	<b>\$ 682,426</b>
<b>Liabilities and Equity</b>			
Current liabilities			
Term facility	6	\$ 24,856	\$ -
Accounts payable and accrued liabilities		40,308	41,795
Current portion of lease liabilities	13	27,944	27,697
		<u>93,108</u>	<u>69,492</u>
Long-term liabilities			
Lease liabilities	13	72,310	75,384
Deferred income taxes	12	41,405	42,955
Due to related parties	16	325	206
Term facility	6	-	24,819
		<u>207,148</u>	<u>212,856</u>
<b>Total Liabilities</b>		<b>207,148</b>	<b>212,856</b>
<b>Equity</b>			
Common share capital	8	715,704	718,790
Contributed surplus	10	6,626	6,308
Accumulated other comprehensive income		19,731	14,194
Merger reserve	2	(488,916)	(488,916)
Retained earnings		226,880	219,194
		<u>480,025</u>	<u>469,570</u>
Commitments and contingencies	15		
<b>Total Liabilities and Equity</b>		<b>\$ 687,173</b>	<b>\$ 682,426</b>

See accompanying notes to the unaudited interim condensed consolidated financial statements.

On behalf of the Board:

“Peter Jelley”  
Director

“Thomas G. Wellner”  
Director

# Andlauer Healthcare Group Inc.

## Interim Condensed Consolidated Statements of Income and Comprehensive Income

For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

	Note	March 31, 2024	March 31, 2023
<b>Revenue</b>	11	<b>\$ 161,138</b>	<b>\$ 164,774</b>
<b>Operating expenses</b>			
Cost of transportation and services		82,466	84,179
Direct operating expenses		26,273	27,035
Selling, general and administrative expenses		12,816	13,110
Depreciation and amortization	4	18,340	16,760
		<u>139,895</u>	<u>141,084</u>
<b>Operating income</b>		<b>21,243</b>	<b>23,690</b>
Interest expense	14	(1,579)	(1,933)
Interest income		695	599
Other income		9	19
		<u></u>	<u></u>
<b>Income before income taxes</b>		<b>20,368</b>	<b>22,375</b>
Current income tax expense	12	7,512	7,685
Deferred income tax recovery	12	(2,067)	(1,838)
		<u>5,445</u>	<u>5,847</u>
<b>Net income</b>		<b>\$ 14,923</b>	<b>\$ 16,528</b>
<b>Net earnings per share</b>			
Basic earnings per share	9	<b>\$ 0.36</b>	<b>\$ 0.39</b>
Diluted earnings per share	9	<b>\$ 0.35</b>	<b>\$ 0.39</b>
<b>Other comprehensive income</b>			
Net income		\$ 14,923	\$ 16,528
Foreign currency translation adjustment		5,537	(200)
Other comprehensive income (loss) for the year		<u>5,537</u>	<u>(200)</u>
<b>Total comprehensive income for the year</b>		<b>\$ 20,460</b>	<b>\$ 16,328</b>

See accompanying notes to the unaudited interim condensed consolidated financial statements.

# Andlauer Healthcare Group Inc.

## Interim Condensed Consolidated Statements of Changes in Equity

### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

	Number of shares (thousands) (note 8)	Share capital (note 8)	Accumulated other compre- hensive income	Merger reserve (note 2)	Contributed surplus (note 10)	Retained earnings	Total equity
Balance at December 31, 2023	41,467	\$ 718,790	\$ 14,194	\$ (488,916)	\$ 6,308	\$ 219,194	\$ 469,570
Net income and comprehensive income for the period	-	-	5,537	-	-	14,923	20,460
Share-based compensation (note 10)	16	90	-	-	318	-	408
Shares repurchased for cancellation (note 8)	(159)	(3,176)	-	-	-	(3,105)	(6,281)
Dividends (note 8)	-	-	-	-	-	(4,132)	(4,132)
<b>Balance at March 31, 2024</b>	<b>41,324</b>	<b>\$ 715,704</b>	<b>\$ 19,731</b>	<b>\$ (488,916)</b>	<b>\$ 6,626</b>	<b>\$ 226,880</b>	<b>\$ 480,025</b>
Balance at December 31, 2022	41,914	\$ 727,835	\$ 19,642	\$ (488,916)	\$ 5,806	\$ 176,625	\$ 440,992
Net income and comprehensive income (loss) for the period	-	-	(200)	-	-	16,528	16,328
Share-based compensation (note 10)	-	-	-	-	225	-	225
Dividends (note 8)	-	-	-	-	-	(3,353)	(3,353)
<b>Balance at March 31, 2023</b>	<b>41,914</b>	<b>\$ 727,835</b>	<b>\$ 19,442</b>	<b>\$ (488,916)</b>	<b>\$ 6,031</b>	<b>\$ 189,800</b>	<b>\$ 454,192</b>

See accompanying notes to the unaudited interim condensed consolidated financial statements.

# Andlauer Healthcare Group Inc.

## Interim Condensed Consolidated Statements of Cash Flow

### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

	Note	March 31, 2024	March 31, 2023
<b>Operating activities</b>			
Net income for the period		\$ 14,923	\$ 16,528
Changes not involving cash:			
Depreciation and amortization		18,340	16,760
Amortization of capitalized financing costs	6	37	67
Share-based compensation	10	408	225
Deferred income tax recovery	12	(2,067)	(1,838)
Loss (gain) on disposal of property, plant and equipment		22	(123)
		<u>31,663</u>	<u>31,619</u>
Changes in non-cash operating working capital:			
Trade and other receivables		2,283	(2,923)
Inventories		25	(264)
Accounts payable and accrued liabilities		(1,601)	(724)
Income taxes		43	(1,339)
Net change in other operating working capital balances		783	(1,973)
<b>Cash flows from operating activities</b>		<b><u>33,196</u></b>	<b><u>24,396</u></b>
<b>Financing activities</b>			
Dividends	8	(4,132)	(3,353)
Principal repayments on lease liabilities	13	(7,184)	(7,171)
Net change in related party balances		188	36
Shares repurchased for cancellation	8	(6,281)	-
<b>Cash flows used in financing activities</b>		<b><u>(17,409)</u></b>	<b><u>(10,488)</u></b>
<b>Investing activities</b>			
Purchase of property, plant and equipment		(7,978)	(5,209)
Proceeds on disposal of property, plant and equipment		281	382
Purchase of intangible assets	5	(332)	(513)
<b>Cash flows used in investing activities</b>		<b><u>(8,029)</u></b>	<b><u>(5,340)</u></b>
<b>Net increase in cash and cash equivalents</b>		<b>7,758</b>	<b>8,568</b>
Effect of foreign currency translation on cash and cash equivalents		660	(27)
<b>Cash and cash equivalents, beginning of period</b>		<b><u>59,740</u></b>	<b><u>65,855</u></b>
<b>Cash and cash equivalents, end of period</b>		<b><u>\$ 68,158</u></b>	<b><u>\$ 74,396</u></b>

See accompanying notes to the unaudited interim condensed consolidated financial statements.

# Andlauer Healthcare Group Inc.

## Notes to Interim Condensed Consolidated Financial Statements

### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

---

#### 1. Reporting entity

Andlauer Healthcare Group Inc. ("AHG", or the "Company") was incorporated under the Ontario Business Corporations Act with its head office located at 100 Vaughan Valley Blvd. in Woodbridge, Ontario. AHG's subordinate voting shares are listed on the Toronto Stock Exchange under the stock symbol "AND". AHG specializes in third party logistics and transportation solutions for the healthcare sector in Canada and the United States.

In addition to the shares issued to the public, Andlauer Management Group Inc. ("AMG") holds 21.84 million multiple voting shares and 10,200 subordinate voting shares of AHG, representing approximately 52.9% of the issued and outstanding shares and 81.8% of the voting power attached to all of the shares. AMG is owned and controlled by Michael Andlauer, Chief Executive Officer, Chief Operating Decision Maker ("CODM"), and a director of AHG.

#### 2. Basis of presentation

##### a) Statement of compliance

These unaudited interim condensed consolidated financial statements ("consolidated financial statements") have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting, as issued by the International Accounting Standards Board ("IASB"). Under International Financial Reporting Standards ("IFRS"), additional disclosures are required in the annual financial statements and therefore, these consolidated financial statements and accompanying notes should be read in conjunction with the notes to the Company's audited consolidated financial statements for the years ended December 31, 2023 and 2022.

These consolidated financial statements have been prepared using consistent accounting policies and methods used in the preparation of the Company's annual audited consolidated financial statements except for changes in the estimated useful lives of certain property, plant and equipment as described in note 4.

These consolidated financial statements were authorized for issue by the Board of Directors effective May 2, 2024.

##### b) Basis of measurement

These consolidated financial statements were prepared on a going concern basis under the historical cost method except for share based compensation and business combinations, which were recorded at fair value.

##### Common control transaction

These consolidated financial statements comprise the results of AHG and Associated Logistics Solutions Inc., Credo Canada Systems Inc., Andlauer Specialized Transportation Inc. (formerly 2186940 Ontario Inc.), Skelton Canada Inc., and their respective subsidiaries. Prior to the Company's initial public offering ("IPO") on December 11, 2019, certain of AHG's subsidiaries (Associated Logistics Solutions Inc., Credo Canada Systems Inc., Andlauer Specialized Transportation Inc. (formerly 2186940 Ontario Inc.) and their respective subsidiaries at that time – collectively, the "AHG Entities") were owned 100% by AMG. Pursuant to a share purchase agreement between AHG and AMG, and in connection with a corporate reorganization immediately prior to the IPO, AHG acquired a 100% ownership interest in the AHG Entities based on the value of consideration of \$577,625. Total net parent investment immediately prior to the IPO was \$88,709. A merger reserve of \$488,916 is recorded to reflect the difference in carrying value of the net assets acquired and the consideration paid since AHG and the AHG Entities were all related parties under common control of AMG at the time of the acquisition. Business combinations involving entities under common control are outside the scope of IFRS 3 Business Combinations. AHG accounted for this common control transaction using book value accounting, based on the book values recognized in the financial statements of the underlying entities.

# Andlauer Healthcare Group Inc.

## Notes to Interim Condensed Consolidated Financial Statements

### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

---

## 2. Basis of presentation (continued)

### c) Basis of consolidation

#### (i) Business combinations

The Company accounts for acquired businesses using the acquisition method of accounting by recording assets acquired and liabilities assumed at their respective fair values. The Company measures goodwill as the fair value of the consideration transferred, including the fair value of liabilities resulting from contingent consideration arrangements, less the net recognized amount of the identifiable assets acquired and liabilities assumed, all measured at fair value as of the acquisition date.

Transaction costs, other than those associated with the issue of debt or equity securities, that the Company incurs in connection with a business combination are expensed as incurred.

#### (ii) Subsidiaries

The consolidated financial statements comprise the financial statements of the Company and its subsidiaries. The Company controls an entity when it is exposed to, or has the right to, variable returns from its involvement with the entity and has the ability to affect those through its power over the entity. The financial statements of subsidiaries are included in the consolidated financial statements from the date that control commences until the date that control ceases. The accounting policies of subsidiaries are aligned with the policies adopted by the Company.

#### (iii) Transactions eliminated on consolidation

Intercompany balances and transactions, and any unrealized income and expenses arising from intercompany transactions, are eliminated in preparing the consolidated financial statements.

### d) Functional and presentation currency

These consolidated financial statements are presented in Canadian dollars, which is the Company's functional currency. All financial information presented in Canadian dollars has been rounded to the nearest thousand. The functional currency of Canadian operations is the Canadian dollar and the functional currency of U.S. operations is the U.S. dollar.

### e) Judgments and estimates

Preparing the consolidated financial statements requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates. In preparing these consolidated financial statements, significant judgments made by management in applying the accounting policies and the key sources of estimation uncertainty were the same as those applied to the consolidated financial statements for the year ended December 31, 2023, except for changes in the estimated useful lives of certain property, plant and equipment as described in note 4.

## 3. Segment reporting

The Company is organized into operating segments, which aggregate into two reportable segments: Specialized Transportation and Healthcare Logistics. The operating segments are managed independently as they require different technology and capital resources. For each of the operating segments, the Company's CODM reviews internal management reports, evaluating the metrics as summarized in the tables that follow.

# Andlauer Healthcare Group Inc.

## Notes to Interim Condensed Consolidated Financial Statements

### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

### 3. Segment reporting (continued)

The Company evaluates performance based on the various financial measures of its operating segments. Performance is measured based on segment income or loss before tax. This measure is included in the internal management reports that are reviewed by the Company's CEO and refers to "Income before income taxes" in the consolidated statements of income and comprehensive income. Segment income or loss before tax is used to measure performance as management believes that such information is the most relevant in evaluating the results of certain segments relative to other entities that operate within the same industries.

The following table identifies selected financial data as at March 31, 2024 and 2023 and for the three months then ended:

	Specialized Transportation	Healthcare Logistics	Corporate	Eliminations	Total
<b>As at March 31, 2024 and for the three months then ended</b>					
Revenue	\$ 132,128	\$ 42,860	\$ 855	\$ (14,705)	\$ 161,138
Segment income before tax	16,420	3,941	7	-	20,368
Interest income	433	231	1,697	(1,666)	695
Interest expense	(1,220)	(359)	-	-	(1,579)
Depreciation and amortization	(14,299)	(4,041)	-	-	(18,340)
Segment net income	12,095	2,992	(164)	-	14,923
Segment total assets	533,129	176,443	670,843	(693,242)	687,173
Additions of ROU assets	4,160	2	-	-	4,162
Capital expenditures	7,535	443	-	-	7,978
Segment total liabilities	153,833	72,686	6,363	(25,734)	207,148
<b>As at March 31, 2023 and for the three months then ended</b>					
Revenue	\$ 132,933	\$ 46,033	\$ 1,785	\$ (15,977)	\$ 164,774
Segment income before tax	17,138	5,057	180	-	22,375
Interest income	(429)	99	929	-	599
Interest expense	(1,097)	(450)	(386)	-	(1,933)
Depreciation and amortization	(12,981)	(3,779)	-	-	(16,760)
Segment net income	12,647	3,768	113	-	16,528
Segment total assets	558,458	178,098	731,461	(749,856)	718,161
Additions of ROU assets	2,924	4	-	-	2,928
Capital expenditures	4,355	854	-	-	5,209
Segment total liabilities	227,892	87,681	30,745	(82,349)	263,969

The Company's Healthcare Logistics segment purchases transportation services from its Specialized Transportation segment. Fees for these services are based on negotiated rates, which approximate fair value, and are reflected as revenues of the Specialized Transportation segment. Rates are adjusted from time to time based on market conditions. The Company also charges fees for services and costs incurred from its corporate office to subsidiaries. Intersegment revenues and expenses and related intersegment payables and receivables are eliminated in the Company's consolidated results.

The Company does not have any customers that individually represent more than 10% of revenue for the periods ended March 31, 2024 and 2023.

# Andlauer Healthcare Group Inc.

## Notes to Interim Condensed Consolidated Financial Statements

### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

#### 4. Property, plant and equipment

Effective January 1, 2024, the Company revised the estimated useful lives and related depreciation methods of certain tangible assets reflecting a reassessment of their expected usefulness to the Company, and recent experience related to their economic lives.

These changes are summarized as follows:

Asset	Depreciation method prior to January 1, 2024	Depreciation method effective January 1, 2024
Furniture and fixtures	20-30% declining balance	7 years straight line
Logistics and transportation equipment	Primarily 20-30% declining balance, except for storage vaults which are amortized straight line over 40 years, and certain transportation equipment which is amortized straight line over periods of 3-7 years	3 to 10 years straight line, except for storage vaults which are amortized straight line over 40 years

The changes in estimates have been made on a prospective basis. For the three months ended March 31, 2024, the changes in estimates increased depreciation expense by \$1,057. The full year impact of the changes in estimates is expected to result in a net reduction of depreciation expense of \$947.

Reconciliation of the net carrying amounts for each class of property, plant and equipment is summarized below:

	Facilities <sup>1</sup>	Furniture and fixtures	Leasehold improvements	Logistics and transportation equipment <sup>1</sup>	Total
<b>Cost</b>					
Balance at December 31, 2023	\$ 164,079	\$ 9,522	\$ 27,044	\$ 217,823	\$ 418,468
Additions	2,760	25	103	9,252	12,140
Dispositions	-	-	-	(1,060)	(1,060)
Foreign currency adjustments	146	9	64	834	1,053
<b>Balance at March 31, 2024</b>	<b>\$ 166,985</b>	<b>\$ 9,556</b>	<b>\$ 27,211</b>	<b>\$ 226,849</b>	<b>\$ 430,601</b>
<b>Accumulated depreciation</b>					
Balance at December 31, 2023	\$ 101,940	\$ 7,593	\$ 16,417	\$ 126,318	\$ 252,268
Depreciation for the period	4,560	358	764	7,614	13,296
Dispositions	-	-	-	(757)	(757)
Foreign currency adjustments	45	2	10	335	392
<b>Balance at March 31, 2024</b>	<b>\$ 106,545</b>	<b>\$ 7,953</b>	<b>\$ 17,191</b>	<b>\$ 133,510</b>	<b>\$ 265,199</b>
<b>Net carrying amounts</b>					
<b>At December 31, 2023</b>	<b>\$ 62,139</b>	<b>\$ 1,929</b>	<b>\$ 10,627</b>	<b>\$ 91,505</b>	<b>\$ 166,200</b>
<b>At March 31, 2024</b>	<b>\$ 60,440</b>	<b>\$ 1,603</b>	<b>\$ 10,020</b>	<b>\$ 93,339</b>	<b>\$ 165,402</b>

<sup>1</sup> Facilities and certain logistics and transportation equipment assets are ROU assets, capitalized in accordance with IFRS 16. Refer to note 13.

# Andlauer Healthcare Group Inc.

## Notes to Interim Condensed Consolidated Financial Statements

### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

## 5. Goodwill and intangible assets

	Goodwill	Customer relationships	Brand	Software	Total
<b>Cost</b>					
Balance at December 31, 2023	\$ 190,560	\$ 163,824	\$ 42,306	\$ 11,941	\$ 408,631
Additions	-	-	-	332	332
Foreign currency adjustments	2,392	2,287	684	11	5,374
<b>Balance at March 31, 2024</b>	<b>\$ 192,952</b>	<b>\$ 166,111</b>	<b>\$ 42,990</b>	<b>\$ 12,284</b>	<b>\$ 414,337</b>
<b>Accumulated amortization</b>					
Balance at December 31, 2023	\$ -	\$ 57,775	\$ 9,795	\$ 6,142	\$ 73,712
Amortization for the period	-	3,761	1,070	213	5,044
Foreign currency adjustments	-	507	151	-	658
<b>Balance at March 31, 2024</b>	<b>\$ -</b>	<b>\$ 62,043</b>	<b>\$ 11,016</b>	<b>\$ 6,355</b>	<b>\$ 79,414</b>
<b>Net carrying amounts</b>					
<b>At December 31, 2023</b>	<b>\$ 190,560</b>	<b>\$ 106,049</b>	<b>\$ 32,511</b>	<b>\$ 5,799</b>	<b>\$ 334,919</b>
<b>At March 31, 2024</b>	<b>\$ 192,952</b>	<b>\$ 104,068</b>	<b>\$ 31,974</b>	<b>\$ 5,929</b>	<b>\$ 334,923</b>

## 6. Credit facilities

	March 31, 2024	December 31, 2023
Term facility	\$ 25,000	\$ 25,000
	25,000	25,000
Less: capitalized financing costs	(144)	(181)
<b>Credit facilities</b>	<b>\$ 24,856</b>	<b>\$ 24,819</b>

Recorded in the consolidated balance sheets as follows:

	March 31, 2024	December 31, 2023
Revolving credit facility	\$ -	\$ -
Term facility	24,856	24,819
<b>Credit facilities</b>	<b>\$ 24,856</b>	<b>\$ 24,819</b>

## Andlauer Healthcare Group Inc.

### Notes to Interim Condensed Consolidated Financial Statements

#### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

## 6. Credit facilities (continued)

The movement in credit facilities from December 31, 2023 is as follows:

	Credit Facilities
Balance at December 31, 2023	\$ 24,819
<b>Non-cash movements</b>	
Amortization of capitalized financing costs	37
<b>Balance at March 31, 2024</b>	<b>\$ 24,856</b>

The Company is party to credit facilities with a syndicate of lenders. The credit facilities comprise a revolving credit facility in the aggregate principal amount of up to \$100,000 and a term facility in the aggregate principal amount of up to \$50,000. The credit facilities will mature and be due and payable on March 1, 2025. There is no repayment schedule for either the revolving credit facility or the term facility, except at maturity. Financing costs of \$621, which apply to the credit facilities in aggregate, were capitalized in the term facility.

The credit facilities are available to be drawn in Canadian dollars by way of prime rate loans, bankers' acceptances and letters of credit, and in U.S. dollars by way of base rate loans, and letters of credit, in each case, plus the applicable margin in effect from time to time. At March 31, 2024, the credit facilities comprise bankers' acceptances drawn at an interest rate of 6.7% (December 31, 2023 – 6.9%).

The credit facilities are guaranteed by each of the Company's material subsidiaries and are secured by (i) a first priority lien over all personal property of the Company, subject to certain exclusions and permitted liens, (ii) charges over certain material leased real property interests, and (iii) a first ranking pledge of 100% of the securities of any subsidiary owned by the Company.

The credit facilities are subject to customary negative covenants and include financial covenants requiring the Company to maintain at all times a maximum net leverage ratio and a minimum interest coverage ratio, tested on a quarterly basis. At March 31, 2024 and December 31, 2023, the Company was in compliance with all of its covenants under the credit facilities.

Amounts recognized in the consolidated statements of income and comprehensive income in connection with interest expense on the credit facilities for the three months ended March 31, 2024 was \$416 (March 31, 2023 – \$795).

# Andlauer Healthcare Group Inc.

## Notes to Interim Condensed Consolidated Financial Statements

### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

## 7. Financial instruments and financial risk management

### Accounting classifications and fair values

The Company's financial instruments consist of cash and cash equivalents, trade and other receivables, long-term deposits and other, accounts payable and accrued liabilities and its credit facilities (refer to note 6). The Company believes that the carrying amount of each of these items is a reasonable approximation of fair value given the short-term nature of the financial instruments.

As the credit facilities bear interest at a floating rate subject to fluctuations in the bank prime rate the carrying value of the debt approximates fair value.

## 8. Share capital

The Company is authorized to issue an unlimited number of subordinate voting common shares, an unlimited number of multiple voting common shares, and an unlimited number of preferred shares, issuable in series. The subordinate voting shares and multiple voting shares rank *pari passu* with respect to the payment of dividends, return of capital and distribution of assets in the event of liquidation, dissolution, or wind-up. Holders of multiple voting shares are entitled to four votes per multiple voting share, and holders of subordinate voting shares are entitled to one vote per subordinate voting share on all matters upon which holders of shares are entitled to vote.

As of March 31, 2024, all of the multiple voting shares and 10,200 subordinate voting shares are owned by AMG. The following table summarizes the number of common shares issued:

	Number of common shares (in thousands)			Share capital (in thousands of dollars)		
	Multiple voting common shares	Subordinate voting common shares	Total common shares	Multiple voting common shares	Subordinate voting common shares	Total share capital
Balance at December 31, 2023	21,840	19,627	41,467	\$ 327,600	\$ 391,190	\$ 718,790
Shares issued in connection with the exercise of options (note 10)	-	16	16	-	90	90
Shares repurchased for cancellation in connection with the Company's normal course issuer bid	-	(159)	(159)	-	(3,176)	(3,176)
<b>Balance at March 31, 2024</b>	<b>21,840</b>	<b>19,484</b>	<b>41,324</b>	<b>\$ 327,600</b>	<b>\$ 388,104</b>	<b>\$ 715,704</b>

# Andlauer Healthcare Group Inc.

## Notes to Interim Condensed Consolidated Financial Statements

### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

## 8. Share capital (continued)

### Normal course issuer bid and automatic securities purchase plan

From time to time, the Company will announce a normal course issuer bid ("NCIB") approved by the Board and the TSX to repurchase and cancel a specified number of subordinate voting shares. All repurchases are made through the facilities of the Toronto Stock Exchange at market prices. Amounts paid above the average book value of the subordinate voting shares are charged to retained earnings. In connection with a NCIB, the Company may enter into an automatic securities purchase plan ("ASPP") with a designated broker for the purpose of permitting the Company to purchase its subordinate voting shares under the NCIB during times when the Company would ordinarily not be permitted to make such purchases due to regulatory restrictions or self-imposed blackout periods. The volume of purchases is determined by the broker in its sole discretion based on purchase price and maximum volume parameters established by the Company in accordance with the rules of the TSX, applicable securities laws and the terms of the ASPP. Any purchases made under an ASPP will be included in computing the number of subordinate voting shares purchased under a NCIB.

On March 24, 2023, the Company announced that the TSX had approved its notice of intention to make a NCIB for up to a maximum of 1,856,857 of its subordinate voting shares, or approximately 10% of its public float as of March 23, 2023, over the 12-month period commencing on March 29, 2023. The bid terminated on March 28, 2024. In connection with the NCIB, the Company established an ASPP with its designated broker that contained specified parameters regarding how its subordinate voting shares may be purchased under the NCIB during self-imposed blackout periods. For the three month period ended March 31, 2024, a total of 159,350 subordinate voting shares, comprising approximately 0.8% of the number of subordinate voting shares outstanding, have been purchased and cancelled pursuant to the NCIB at an average price of \$39.42 per share, for a total purchase price of approximately \$6,281. The excess of the purchase price paid over the average carrying value of the subordinate voting shares purchased and cancelled, in the amount of \$3,105, was recognized as a share repurchase premium and a reduction to retained earnings.

### Dividends to subordinate voting and multiple voting shareholders

During the three months ended March 31, 2024, the Company declared total dividends of \$4,132, or \$0.10 per common share (March 31, 2023 – \$3,353, or \$0.08 per common share), on subordinate voting and multiple voting shares. These amounts were included in accounts payable and accrued liabilities as at March 31, 2024 and 2023 respectively, and were paid on April 15, 2024 and April 17, 2023 respectively, to common shareholders of record on March 28, 2024 and March 31, 2023 respectively.

## 9. Earnings per share

### Basic earnings per share

The basic earnings per share and the weighted average number of common shares outstanding have been calculated as follows:

	Three Months Ended March 31, 2024	Three Months Ended March 31, 2023
(in thousands of dollars and number of shares)		
Net income	\$ 14,923	\$ 16,528
Weighted average number of common shares	41,384	41,914
<b>Earnings per share – basic</b>	<b>\$ 0.36</b>	<b>\$ 0.39</b>

## Andlauer Healthcare Group Inc.

### Notes to Interim Condensed Consolidated Financial Statements

#### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

## 9. Earnings per share (continued)

### Diluted earnings per share

The basic earnings per share and the weighted average number of common shares outstanding after adjustment for the effects of all dilutive common shares have been calculated as follows:

	Three Months Ended March 31, 2024	Three Months Ended March 31, 2023
(in thousands of dollars and number of shares)		
Net income	\$ 14,923	\$ 16,528
Weighted average number of common shares	41,384	41,914
Dilutive effects:		
Stock options	641	728
Restricted share units	30	-
Deferred share units	57	51
Weighted average number of diluted common shares	42,112	42,693
Earnings per share – diluted	\$ 0.35	\$ 0.39

## 10. Share-based payment arrangements

### Stock option plan (equity settled)

The Company offers a stock option plan for the benefit of certain of its employees. Each stock option entitles its holder to receive one subordinate voting common share upon exercise. The exercise price payable for each option is determined by the Board of Directors at the date of grant. The options vest in equal installments over four years and the expense is recognized following the treasury method as each installment is fair valued separately and recorded over the respective vesting periods.

On December 11, 2019, the Board of Directors approved a grant of 1.65 million options. Of these options, 25 thousand were exercised during the three months ended March 31, 2024 (March 31, 2023 – nil) while 1.018 million remain outstanding and are exercisable. On December 11, 2023, the Board of Directors approved a grant of 63 thousand options which were granted to executive officers and management personnel in connection with its long-term incentive plan. Of these options, 2 thousand were forfeited during the three months ended March 31, 2024 (March 31, 2023 - nil).

Of the options outstanding at March 31, 2024, a total of 635 thousand (March 31, 2023 – 635 thousand) are held by non-executive directors; 204 thousand (March 31, 2023 – 200 thousand) are held by executive officers; with the remaining 240 thousand (March 31, 2023 – 239 thousand) held by management personnel.

# Andlauer Healthcare Group Inc.

## Notes to Interim Condensed Consolidated Financial Statements

### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

## 10. Share-based payment arrangements (continued)

### Stock option plan (equity-settled) (continued)

The table below summarizes the changes in the outstanding stock options:

(in thousands of options and in dollars)	<u>March 31, 2024</u>		<u>March 31, 2023</u>	
	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price
Opening balance	1,106	\$ 16.41	1,074	\$ 15.00
Exercised	(25)	15.00	-	-
Forfeited	(2)	\$ 39.73	-	-
Ending balance	1,079	\$ 16.40	1,074	\$ 15.00
<b>Options exercisable</b>	<b>1,018</b>	<b>\$ 15.00</b>	<b>780</b>	<b>\$ 15.00</b>

The table below summarizes stock options outstanding and exercisable at March 31, 2024:

(in thousands of options and in dollars)	<u>Options Outstanding</u>		<u>Options Exercisable</u>
	Number of options	Weighted average remaining contractual life (in years)	Number of options
<b>Exercise price</b>			
\$ 15.00	1,018	5.70	1,018
39.73	61	9.70	-
	<b>1,079</b>	<b>5.93</b>	<b>1,018</b>

The Company recognized compensation expense of \$114 for the three months ended March 31, 2024 (March 31, 2023 – \$70), with corresponding increases to contributed surplus in connection with the vesting of options.

During the three months ended March 31, 2024, 25 thousand options were exercised on a cashless basis resulting in 16 thousand subordinate voting common shares being issued from treasury and in the surrender of 9 thousand options used to fund the cashless option exercise. The volume weighted average price used to calculate the cashless exercises in accordance with the Company's Omnibus Equity Incentive Plan was \$42.77 per share at the time of exercise resulting in a \$90 net increase in share capital. When options are exercised, the option value that was originally recognized is transferred from contributed surplus to share capital. The transfer of the option value of the options exercised resulted in a \$90 reduction to contributed surplus at \$3.60 per share.

### Restricted share units ("RSUs") program (equity settled)

On December 11, 2023, the Board of Directors approved a grant of 30 thousand RSUs which were granted to executive officers and management personnel in connection with its long-term incentive plan. The fair value of the RSUs is determined to be the share price fair value at the date of the grant. The RSUs vest in equal installments over four years and the expense is recognized as a share-based compensation expense, through contributed surplus over the vesting period. The fair value of the RSUs granted was \$39.95 per unit. For the three months ended March 31, 2024 the Company recognized a compensation expense of \$156, with a corresponding increase to contributed surplus (March 31, 2023 – \$nil).

## Andlauer Healthcare Group Inc.

### Notes to Interim Condensed Consolidated Financial Statements

#### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

## 10. Share-based payment arrangements (continued)

### Restricted share units ("RSUs") program (equity settled) (continued)

The table below summarizes the changes in the outstanding RSUs:

(in thousands of RSUs and in dollars)	March 31, 2024	
	Number of RSUs	Weighted average grant date fair value
Opening balance	30	\$ 39.95
Ending balance	30	\$ 39.95
<b>RSUs exercisable</b>	<b>-</b>	<b>\$ 39.95</b>

### Director deferred share units ("DSUs") program (equity settled)

Each non-executive director receives at least 50% of their annual director retainer in DSUs. DSUs vest when granted but are not redeemable for settlement until the director ceases to be a member of the Board. The number of DSUs issued is calculated for each director as the director's quarterly retainer divided by the volume weighted average trading price on the TSX for the five trading days prior to such issuance. For the three months ended March 31, 2024, the Company recognized a compensation expense of \$138, with corresponding increases to contributed surplus (March 31, 2023 – \$155).

The table below summarizes the changes in the outstanding DSUs:

(thousands of DSUs)	March 31, 2024	March 31, 2023
Opening balance	57	51
Granted	3	3
<b>Ending balance</b>	<b>60</b>	<b>54</b>

# Andlauer Healthcare Group Inc.

## Notes to Interim Condensed Consolidated Financial Statements

### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

## 11. Revenue

### a) Revenue streams

The Company generates revenue primarily from the provision of supply chain transportation and logistics services to its customers. The Company's contracts are typically satisfied over a short period of time. Consequently, the Company applies the practical expedient and does not disclose information related to its remaining performance obligations.

### b) Disaggregation of revenue from contracts with customers

In the following table, revenue from contracts with customers is disaggregated by major products and service lines. The table also includes a reconciliation of the disaggregated revenue with the Company's reportable segments (note 3), and revenue disaggregated by primary geographical markets. All of the revenue generated in the United States comprises ground transportation revenue.

	March 31, 2024	March 31, 2023
<b>Major products/service lines</b>		
Logistics and distribution	\$ 37,918	\$ 40,523
Packaging solutions	4,942	5,510
<b>Healthcare Logistics segment</b>	<b>42,860</b>	<b>46,033</b>
Ground transportation	106,388	108,260
Air freight forwarding	7,995	7,542
Dedicated and last mile delivery	17,745	17,131
Intersegment revenue	(13,850)	(14,192)
<b>Specialized Transportation segment</b>	<b>118,278</b>	<b>118,741</b>
<b>Total revenue</b>	<b>\$ 161,138</b>	<b>\$ 164,774</b>

  

	March 31, 2024	March 31, 2023
<b>Primary geographical markets</b>		
Canada	\$ 131,736	\$ 131,046
United States	29,402	33,728
<b>Total revenue</b>	<b>\$ 161,138</b>	<b>\$ 164,774</b>

# Andlauer Healthcare Group Inc.

## Notes to Interim Condensed Consolidated Financial Statements

### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

## 12. Income taxes

### a) Amounts recognized in income or loss

	Three Months Ended March 31, 2024	Three Months Ended March 31, 2023
<b>Current income tax expense:</b>		
Current taxes on income for the reporting year	\$ 7,216	\$ 7,685
Current taxes relating to previous years and other adjustments	296	-
	7,512	7,685
<b>Deferred income tax recovery:</b>		
Recognition of tax benefits related to loss for the period	(18)	(170)
Origination and reversal of temporary differences	(1,761)	(1,668)
Deferred taxes relating to previous years and other adjustments	(288)	-
	(2,067)	(1,838)
<b>Income tax expense reported to the statements of income and comprehensive income</b>	<b>\$ 5,445</b>	<b>\$ 5,847</b>

Total cash outflow for actual taxes paid for the three months ended March 31, 2024 was \$7,360 (March 31, 2023 – \$8,908).

### b) Reconciliation of effective tax rate

	Three Months Ended March 31, 2024	Three Months Ended March 31, 2023
Income before income taxes	\$ 20,368	\$ 22,375
Consolidated Canadian federal and provincial income tax rate	26.5%	26.5%
Income tax expense based on statutory rate	5,398	5,929
Increase (decrease) in income taxes resulting from non-deductible items or other adjustments	47	(82)
<b>Total income tax expense</b>	<b>\$ 5,445</b>	<b>\$ 5,847</b>

### c) Deferred taxes

	March 31, 2024	December 31, 2023
Deferred tax assets	\$ 5,114	\$ 5,285
Deferred tax liabilities	(41,405)	(42,955)
<b>Net deferred tax liability</b>	<b>\$ (36,291)</b>	<b>\$ (37,670)</b>

# Andlauer Healthcare Group Inc.

## Notes to Interim Condensed Consolidated Financial Statements

### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

## 12. Income taxes (continued)

### d) Movement in deferred tax balances

	March 31, 2024	Recognized in income or loss	Foreign currency adjustments	December 31, 2023
Plant and equipment	\$ (11,971)	\$ 955	\$ (139)	\$ (12,787)
Accounts payable and accrued liabilities	1,043	174	1	868
Intangibles	(32,880)	1,280	(580)	(33,580)
Benefit of losses carried forward	2,622	91	-	2,531
Leases	3,943	(166)	30	4,079
Transaction costs	952	(267)	-	1,219
<b>Net deferred tax liability</b>	<b>\$ (36,291)</b>	<b>\$ 2,067</b>	<b>\$ (688)</b>	<b>\$ (37,670)</b>

	December 31, 2023	Recognized in income or loss	Foreign currency adjustments	March 31, 2023
Plant and equipment	\$ (12,787)	\$ 308	\$ 138	\$ (13,233)
Accounts payable and accrued liabilities	868	10	(1)	859
Intangibles	(33,580)	3,635	588	(37,803)
Benefit of losses carried forward	2,531	(422)	(23)	2,976
Leases	4,079	(183)	(30)	4,292
Transaction costs	1,219	(757)	1	1,975
<b>Net deferred tax liability</b>	<b>\$ (37,670)</b>	<b>\$ 2,591</b>	<b>\$ 673</b>	<b>\$ (40,934)</b>

	March 31, 2023	Recognized in income or loss	Foreign currency adjustments	December 31, 2022
Plant and equipment	\$ (13,233)	\$ 564	\$ 6	\$ (13,803)
Accounts payable and accrued liabilities	859	40	-	819
Intangibles	(37,803)	1,244	-	(39,047)
Benefit of losses carried forward	2,976	170	23	2,783
Leases	4,292	98	-	4,194
Transaction costs	1,975	(278)	(1)	2,254
<b>Net deferred tax (liability) asset</b>	<b>\$ (40,934)</b>	<b>\$ 1,838</b>	<b>\$ 28</b>	<b>\$ (42,800)</b>

# Andlauer Healthcare Group Inc.

## Notes to Interim Condensed Consolidated Financial Statements

### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

## 12. Income taxes (continued)

### e) Unrecognized deferred tax liabilities

As at March 31, 2024, temporary differences of \$40,390 (December 31, 2023 – \$40,390) exist in connection with wholly-owned investments in subsidiaries; and the related potential deferred tax liability of \$5,352 (December 31, 2023 – \$5,352) has not been recognized. The Company controls the dividend policies of its subsidiaries and controls the timing of payment of such dividends. Accordingly, the Company controls the timing of reversal of the related taxable temporary differences; and management is satisfied that they will not reverse in the foreseeable future.

### f) Non-capital loss carryforwards

The Company recognized deferred tax assets in connection with certain losses for the current year on the basis that it will have sufficient future taxable profit.

The Company has total non-capital tax loss carry forwards of \$10,096 that begin to expire in 2039.

### g) Uncertainty over income tax treatments

The calculation of current and deferred income taxes requires management to make certain judgements regarding the tax rules in jurisdictions where the Company performs activities. The Company believes that its accruals for tax liabilities are adequate for all open tax years based on its assessment of many factors, including interpretations of tax law and prior experience.

## 13. Leases

The Company leases buildings and equipment in the operation of its Transportation and Logistics businesses. The Company is required to estimate the incremental borrowing rates used to discount lease liabilities if the interest rate implicit in the lease is not readily determined. The Company estimates its incremental borrowing rates for portfolios of leases with similar characteristics, such as similar risk profiles, same or similar types of security, and similar lease terms. Building lease terms range from 5 to 10 years. Facilities lease liabilities are calculated using the Company's incremental borrowing rate based on the specific lease commitments and term for each facility. The average incremental borrowing rate for facilities for the three months ended March 31, 2024 is 5.55% (year ended December 31, 2023 – 5.76%). Equipment lease terms range from 1 to 7 years. Equipment lease liabilities are calculated using the operating segment's average incremental borrowing rate on an equipment lease portfolio basis for that period. The average incremental borrowing rate for equipment for the three months ended March 31, 2024 is 5.70% for Specialized Transportation and 8.66% for Healthcare Logistics (year ended December 31, 2023 – 5.94% for Specialized Transportation; 5.74% for Healthcare Logistics).

Right-of-use assets – Facilities	As at and for the three months ended March 31, 2024	As at and for the year ended December 31, 2023
Opening balance	\$ 62,141	\$ 77,701
Add: additions	2,760	2,477
Less: depreciation	(4,560)	(17,934)
Foreign currency adjustments	101	(103)
<b>Ending balance</b>	<b>\$ 60,442</b>	<b>\$ 62,141</b>

# Andlauer Healthcare Group Inc.

## Notes to Interim Condensed Consolidated Financial Statements

### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

### 13. Leases (continued)

Right-of-use assets – Logistics and transportation equipment	As at and for the three months ended March 31, 2024	As at and for the year ended December 31, 2023
Opening balance	\$ 35,629	\$ 32,333
Add: additions	1,402	15,010
Less: depreciation	(3,575)	(11,691)
Foreign currency adjustments	36	(23)
<b>Ending balance</b>	<b>\$ 33,492</b>	<b>\$ 35,629</b>
Net carrying amounts of right-of-use assets included in property, plant and equipment	March 31, 2024	December 31, 2023
Facilities	\$ 60,442	\$ 62,141
Logistics and transportation equipment	33,492	35,629
<b>Balance</b>	<b>\$ 93,934</b>	<b>\$ 97,770</b>
Lease liabilities – Facilities	As at and for the three months ended March 31, 2024	As at and for the year ended December 31, 2023
Opening balance	\$ 71,501	\$ 86,925
Add: additions	2,760	2,477
Add: interest expense	771	3,085
Less: principal repayments	(4,597)	(17,794)
Less: interest payments	(771)	(3,085)
Foreign currency adjustments	106	(107)
<b>Ending balance</b>	<b>\$ 69,770</b>	<b>\$ 71,501</b>
Lease liabilities – Logistics and transportation equipment	As at and for the three months ended March 31, 2024	As at and for the year ended December 31, 2023
Opening balance	\$ 31,580	\$ 26,804
Add: additions	1,402	15,010
Add: interest expense	392	1,321
Less: principal repayments	(2,587)	(10,158)
Less: interest payments	(392)	(1,321)
Foreign currency adjustments	89	(76)
<b>Ending balance</b>	<b>\$ 30,484</b>	<b>\$ 31,580</b>
Cash lease principal payments	Three months ended March 31, 2024	Year ended December 31, 2023
Repayments of lease principal	\$ (7,184)	\$ (27,952)
<b>Total lease payments</b>	<b>\$ (7,184)</b>	<b>\$ (27,952)</b>

## Andlauer Healthcare Group Inc.

### Notes to Interim Condensed Consolidated Financial Statements

#### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

### 13. Leases (continued)

Lease liabilities	March 31, 2024	December 31, 2023
Facilities	\$ (69,770)	\$ (71,501)
Logistics and transportation equipment	(30,484)	(31,580)
<b>Balance</b>	<b>\$ (100,254)</b>	<b>\$ (103,081)</b>
<b>Lease liabilities included in consolidated balance sheets</b>	<b>March 31, 2024</b>	<b>December 31, 2023</b>
Current	\$ (27,944)	\$ (27,697)
Non-current	(72,310)	(75,384)
<b>Balance</b>	<b>\$ (100,254)</b>	<b>\$ (103,081)</b>
<b>Maturity analysis for lease liabilities – contractual undiscounted cash flows</b>	<b>March 31, 2024</b>	<b>December 31, 2023</b>
Less than one year	\$ 30,992	\$ 32,285
One to 5 years	74,413	76,377
More than 5 years	3,875	5,636
<b>Total undiscounted lease liabilities</b>	<b>\$ 109,280</b>	<b>\$ 114,298</b>

Amounts recognized in the consolidated statements of income and comprehensive income in connection with interest expense for lease liabilities for the three months ended March 31, 2024 was \$1,163 (March 31, 2023 – \$1,138). Total cash outflow for leases for the three months ended March 31, 2024 was \$8,347 (March 31, 2023 – \$8,309).

### 14. Interest expense

Interest expense recognized in income and comprehensive income	March 31, 2024	March 31, 2023
Leases	\$ 1,163	\$ 1,138
Credit facilities	416	795
<b>Total interest expense</b>	<b>\$ 1,579</b>	<b>\$ 1,933</b>

Interest expense recognized in the consolidated statements of income and comprehensive income equates to total interest paid for the periods ended March 31, 2024 and 2023.

# **Andlauer Healthcare Group Inc.**

## **Notes to Interim Condensed Consolidated Financial Statements**

### **For the three months ended March 31, 2024 and 2023**

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

---

#### **15. Commitments and contingencies**

- a) The Company is, from time to time, involved in claims, legal proceedings and complaints arising in the normal course of business and provisions for such claims have been recorded where appropriate. The Company does not believe the final determination of these claims will have an adverse material effect on its consolidated financial statements.
- b) As at March 31, 2024, the Company had outstanding letters of guarantee in the amount of \$365 (December 31, 2023 – \$365).
- c) The Company has made commitments to lease fleet equipment, with the terms to begin upon delivery of the equipment. Commitments range from 72 to 84 months and total \$13,482 (December 31, 2023 – \$12,926).
- d) The Company has made commitments to purchase fleet equipment totalling approximately \$2,364 (December 31, 2023 – \$4,848).

#### **16. Related parties**

During the period, the Company entered into transactions with related parties that were incurred in the normal course of business. The Company's policy is to conduct all transactions and settle all balances with related parties on market terms and conditions. All outstanding balances with these related parties are to be settled in cash within two months of the reporting date. None of the balances are secured. No expense has been recognized in the current period or prior period for bad or doubtful debts in respect of amounts owed by related parties.

The Company is indirectly controlled by Michael Andlauer, the Chief Executive Officer and CODM. Included in these consolidated financial statements are the following transactions and balances with companies related either directly or indirectly to Mr. Andlauer.

The Company recovers certain facilities lease costs from Andlauer Management Group Inc. ("AMG"). The Company also provides certain shared services (primarily accounting services) to AMG.

# Andlauer Healthcare Group Inc.

## Notes to Interim Condensed Consolidated Financial Statements

### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

#### 16. Related parties (continued)

	March 31, 2024	March 31, 2023
<b>Revenue</b>		
<b>Transportation services</b>		
1708998 Ontario Limited (Medical Courier Services)	\$ 51	\$ 56
<b>Shared service recovery</b>		
Andlauer Properties and Leasing Inc.	-	5
Andlauer Management Group Inc.	-	4
9143-5271 Quebec Inc.	-	8
1708998 Ontario Limited (Medical Courier Services)	-	6
<b>Expenses</b>		
<b>Transportation services</b>		
1708998 Ontario Limited (Medical Courier Services)	52	44
Med Express Ltd.	-	10
<b>Contract labour services</b>		
Ready Staffing Solutions Inc.	1,547	1,693
<b>Equipment rent</b>		
Andlauer Properties and Leasing Inc.	642	500
<b>Facility rent</b>		
Andlauer Properties and Leasing Inc.	547	588
9143-5271 Quebec Inc.	387	383

# Andlauer Healthcare Group Inc.

## Notes to Interim Condensed Consolidated Financial Statements

### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

#### 16. Related parties (continued)

	March 31, 2024	December 31, 2023
<b>Trade receivables due from related parties</b>		
Andlauer Properties and Leasing Inc.	\$ 13	\$ 13
1708998 Ontario Limited (Medical Courier Services)	19	41
	32	54
<b>Due from related parties</b>		
Andlauer Management Group Inc.	8	1
Andlauer Properties and Leasing Inc.	100	-
	108	1
<b>Total due from related parties</b>	<b>\$ 140</b>	<b>\$ 55</b>
<b>Trade payables due to related parties</b>		
Ready Staffing Solutions Inc.	\$ 399	\$ 150
1708998 Ontario Limited (Medical Courier Services)	31	13
Andlauer Properties and Leasing Inc.	79	287
Andlauer Management Group Inc.	9	-
	518	450
<b>Due to related parties</b>		
Andlauer Properties and Leasing Inc.	325	206
<b>Total due to related parties</b>	<b>\$ 843</b>	<b>\$ 656</b>

#### Key management personnel

The Company's key management personnel, and persons connected with them, are also considered to be related parties for disclosure purposes. Key management personnel are defined as those individuals having authority and responsibility for planning, directing and controlling the activities of the Company and include the Company's CEO, four named executive officers comprising key management and the Board of Directors.

Key management personnel compensation comprised the following for the three-month periods ended:

	March 31, 2024	March 31, 2023
<b>Key management compensation</b>		
Salaries and benefits	\$ 1,011	\$ 1,015
Share-based payment arrangements	120	44
Director deferred share units	138	155
<b>Total key management compensation</b>	<b>\$ 1,269</b>	<b>\$ 1,214</b>

## Andlauer Healthcare Group Inc.

### Notes to Interim Condensed Consolidated Financial Statements

#### For the three months ended March 31, 2024 and 2023

(In thousands of Canadian dollars, except shares, share price and earnings per share) (unaudited)

## 17. Capital management

The Company's policy is to maintain a strong capital base so as to maintain investor, creditor and market confidence and to sustain future development of the business. Management monitors the return on capital, as well as the level of dividends and distributions to ordinary shareholders.

The Board of Directors seeks to maintain a balance between the higher returns that might be possible with higher levels of borrowing and the advantages and security afforded by a sound capital position. The Company monitors capital using a net leverage ratio, calculated as net debt divided by the last twelve months' earnings before interest, taxes, depreciation and amortization ("EBITDA"). The Company seeks to keep its net leverage ratio below 3.0 in the ordinary course of business.

	March 31, 2024	December 31, 2023
Total lease liabilities	\$ 100,254	\$ 103,081
Term facility	24,856	24,819
Less: cash and cash equivalents	(68,158)	(59,740)
Net debt	56,952	68,160
Last twelve months' net income	49,612	66,140
Last twelve months' interest income	(3,266)	(3,170)
Last twelve months' interest expense	7,853	8,207
Last twelve months' income tax expense	24,065	24,467
Last twelve months' depreciation and amortization	69,729	68,149
EBITDA	147,993	163,793
Net leverage ratio	0.38	0.42